WO2022225712A1 - Solid state forms of firibastat and processes for preparation thereof - Google Patents
Solid state forms of firibastat and processes for preparation thereof Download PDFInfo
- Publication number
- WO2022225712A1 WO2022225712A1 PCT/US2022/023758 US2022023758W WO2022225712A1 WO 2022225712 A1 WO2022225712 A1 WO 2022225712A1 US 2022023758 W US2022023758 W US 2022023758W WO 2022225712 A1 WO2022225712 A1 WO 2022225712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- firibastat
- theta
- crystalline
- degrees
- piperazine
- Prior art date
Links
- HJPXZXVKLGEMGP-YUMQZZPRSA-N (3s)-3-amino-4-[[(2s)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CC[C@H](N)CSSC[C@@H](N)CCS(O)(=O)=O HJPXZXVKLGEMGP-YUMQZZPRSA-N 0.000 title claims abstract description 397
- 229950009620 firibastat Drugs 0.000 title claims abstract description 340
- 238000000034 method Methods 0.000 title claims abstract description 161
- 239000007787 solid Substances 0.000 title claims abstract description 134
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 230000008569 process Effects 0.000 title abstract description 97
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 80
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 117
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 114
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 206010020772 Hypertension Diseases 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 20
- -1 Firibastat piperazine salt Chemical class 0.000 claims description 13
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 abstract description 94
- 150000003839 salts Chemical class 0.000 abstract description 23
- 239000002904 solvent Substances 0.000 description 98
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 94
- 239000002002 slurry Substances 0.000 description 87
- 239000000047 product Substances 0.000 description 82
- 239000011541 reaction mixture Substances 0.000 description 53
- 239000000203 mixture Substances 0.000 description 52
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 40
- 229930182821 L-proline Natural products 0.000 description 36
- 229960002429 proline Drugs 0.000 description 36
- 239000002253 acid Substances 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 27
- 235000002639 sodium chloride Nutrition 0.000 description 25
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 21
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical group C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 21
- 235000019371 penicillin G benzathine Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000001035 drying Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 239000002798 polar solvent Substances 0.000 description 15
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 235000011054 acetic acid Nutrition 0.000 description 10
- 229940098779 methanesulfonic acid Drugs 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 239000013557 residual solvent Substances 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 7
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- DSGUSEBCDAKBCM-UHFFFAOYSA-N ethane-1,2-disulfonic acid;dihydrate Chemical compound O.O.OS(=O)(=O)CCS(O)(=O)=O DSGUSEBCDAKBCM-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 150000007524 organic acids Chemical group 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 150000004684 trihydrates Chemical group 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 239000003849 aromatic solvent Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- RBOXVHNMENFORY-UHFFFAOYSA-N 9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol Chemical compound C1C(N(CCC234)C)C2CCC(O)C3OC2=C4C1=CC=C2OC RBOXVHNMENFORY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004097 EU approved flavor enhancer Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005388 cross polarization Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003759 ester based solvent Substances 0.000 description 2
- 239000004210 ether based solvent Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019264 food flavour enhancer Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000206576 Chondrus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006485 Glutamyl Aminopeptidase Human genes 0.000 description 1
- 108010058940 Glutamyl Aminopeptidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure encompasses solid state forms of Firibastat and salts or co crystals thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
- Firibastat (Sri ⁇ AFd ⁇ -DithiobisP-amino-l-butanesulfonic acid], has the following chemical structure:
- Firibastat is a prodrug of the APA inhibitor EC33, an inhibitor of aminopeptidase A, and it is developed for the treatment of hypertension.
- Polymorphism the occurrence of different crystalline forms, is a property of some molecules and molecular complexes.
- a single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differential scanning calorimetry (“DSC”)), X-ray diffraction (XRD) pattern, infrared absorption fingerprint, and solid state ( 13 C) NMR spectrum.
- TGA thermogravimetric analysis
- DSC differential scanning calorimetry
- XRD X-ray diffraction
- 13 C solid state
- Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
- New solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
- New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemical/physical stability). For at least these reasons, there is a need for additional solid state forms (including solvated forms) of Firibastat.
- the present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat; processes for preparation thereof, and pharmaceutical compositions thereof. These crystalline polymorphs and crystalline salts and co-crystals can be used to prepare other solid state forms of Firibastat, Firibastat co-crystals, Firibastat salts and their solid state forms.
- the present disclosure also provides uses of the said solid state forms of Firibastat, Firibastat co-crystals and/or Firibastat salts in the preparation of other solid state forms of Firibastat or Firibastat co-crystals or salts thereof.
- the present disclosure also provides the said solid state forms of Firibastat, Firibastat, co-crystals and/or Firibastat salts for use in the preparation of other solid state forms of Firibastat, or Firibastat, co-crystals or salts thereof.
- the present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat for use in the preparation of pharmaceutical compositions and/or formulations for use in medicine, including for the treatment of hypertension.
- the present disclosure also encompasses the use of crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure for the preparation of pharmaceutical compositions and/or formulations.
- the present disclosure provides pharmaceutical compositions including crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts according to the present disclosure.
- the present disclosure encompasses pharmaceutical formulations including any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts or pharmaceutical compositions including the described crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts and at least one pharmaceutically acceptable excipient.
- the present disclosure includes processes for preparing the above mentioned pharmaceutical compositions.
- the processes include combining any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts with at least one pharmaceutically acceptable excipient.
- the crystalline polymorphs of Firibastat, as well as co-crystals and/or salts of Firibastat as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorph of Firibastat, Firibastat co-crystals and/or Firibastat salts may be used as medicaments, such as for the treatment of hypertension.
- the present disclosure also provides methods of treating hypertension, by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from hypertension, or otherwise in need of the treatment.
- the present disclosure also provides uses of crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure, or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating e.g., hypertension.
- Figure 1 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form HI;
- Figure 2 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form H2;
- Figure 3 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form A
- Figure 4 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form B
- Figure 5 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat crystal Form El;
- Figure 6 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat: piperazine Form PI;
- Figure 7 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat: L-proline Form P2;
- Figure 8 shows a characteristic solid state 13 C-NMR of Firibastat Form A (200-0 ppm);
- Figure 8A shows a characteristic solid state 13 C-NMR of Firibastat Form A (100-0 ppm);
- Figure 9 shows a characteristic solid state 13 C-NMR of Firibastat crystal Form El (200-0 ppm).
- Figure 9 A shows a characteristic solid state 13 C-NMR of Firibastat crystal Form EIQOO-O ppm).
- the present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat; processes for preparation thereof, and pharmaceutical compositions thereof.
- Solid state properties of Firibastat and crystalline polymorphs thereof can be influenced by controlling the conditions under which Firibastat and crystalline polymorphs thereof are obtained in solid form.
- a solid state form (or polymorph) may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms.
- the expression “substantially free of any other forms” will be understood to mean that the solid state form contains about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD.
- a crystalline polymorph of Firibastat described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w/w), greater than about 90% (w/w), greater than about 95% (w/w), greater than about 98% (w/w), greater than about 99% (w/w), or about 100% of the subject crystalline polymorph of Firibastat
- the described crystalline polymorph of Firibastat may contain from about 1% to about 20% (w/w), from about 5% to about 20% (w/w), or from about 5% to about 10% (w/w) of one or more other crystalline polymorph of the same Firibastat.
- the crystalline polymorphs of Firibastat of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density.
- the crystalline polymorph as described in any aspect or embodiment of the present disclosure may be stable, for example to conditions of high relative humidity, and/or may be thermally stable. Crystalline Forms A, B, El, PI and P2 as described in any aspect or embodiment of the present disclosure, may be especially stable to conditions of high relative humidity and/or may be thermally stable.
- a solid state form such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure.
- Such data include, for example, powder X-ray diffractograms and solid state NMR spectra.
- the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone.
- a crystal form of Firibastat referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Firibastat characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
- anhydrous in relation to crystalline forms of Firibastat, relates to a crystalline form of Firibastat which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, an “anhydrous” form would generally not contain more than 1% (w/w), of either water or organic solvents as measured for example by TGA.
- solvate refers to a crystal form that incorporates a solvent in the crystal structure.
- the solvent is water, the solvate is often referred to as a "hydrate.”
- the solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
- Co-Crystal or “Co-crystal” as used herein is defined as a crystalline material including two or more molecules in the same crystalline lattice and associated by non-ionic and non-covalent bonds. In some embodiments, the co-crystal includes two molecules which are in natural state.
- crystalline Firibastat piperazine is a distinct molecular species
- Crystalline Firibastat: piperazine may be a co-crystal of Firibastat and piperazine.
- crystalline Firibastat: piperazine may be a salt (Firibastat piperazinium).
- Firibastat: piperazine is a salt.
- the molar ratio between Firibastat and piperazine is between 1: 1.5 and 1.5: 1, preferably between 1: 1.25 and 1.25: 1, about 1:2 or in other embodiments about 1:1, and preferably about 1:2.
- crystalline Firibastat: L-Proline is a distinct molecular species and/or a distinct crystalline phase.
- Crystalline Firibastat L-Proline may be a co-crystal of Firibastat and L-Proline.
- crystalline Firibastat L-Proline may be a salt.
- the molar ratio between the active pharmaceutical ingredient (Firibastat) and the coformer (L- Proline) is between 1:3 and 3:1, preferably between 1:2.5 and 2.5:1, in other embodiments about 1:2.
- the term "isolated" in reference to crystalline polymorph of Firibastat, of the present disclosure corresponds to a crystalline polymorph of Firibastat that is physically separated from the reaction mixture in which it is formed.
- a thing e.g., a reaction mixture
- room temperature or “ambient temperature,” often abbreviated as “RT.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located.
- room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
- the amount of solvent employed in a chemical process may be referred to herein as a number of “volumes” or “vol” or “V.”
- a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent.
- this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending a 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent.
- v/v may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v/v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.
- a process or step may be referred to herein as being carried out “overnight.” This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.
- reduced pressure refers to a pressure that is less than atmospheric pressure.
- reduced pressure is about 10 mbar to about 50 mbar.
- ambient conditions refer to atmospheric pressure and a temperature of 22-24°C.
- the present disclosure includes a crystalline polymorph of Firibastat, designated Form HI.
- Crystalline Form HI of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 1; an X-ray powder diffraction pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2- theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
- Crystalline Form HI of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 18.0, 20.4, 21.9, 23.2 and 26.2 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Crystalline Form HI of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 17.8, 18.0, 18.6, 19.6, 20.4, 21.7, 21.9, 23.2, 24.4 and 26.2 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- crystalline Form HI of Firibastat is isolated. Particularly, crystalline Form HI of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
- Crystalline Form HI of Firibastat may be a hydrate.
- crystalline Form HI may contain about 0.5 % to about 5 % of water.
- Crystalline Form HI may be polymorphically pure.
- Crystalline Form HI of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 1; and combinations thereof.
- the present disclosure includes a crystalline polymorph of Firibastat, designated Form H2.
- Crystalline Form H2 of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 2; an X-ray powder diffraction pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2- theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
- Crystalline Form H2 of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 14.5, 20.2, 21.4, 22.5 and 28.6 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Crystalline Form HI of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 14.5, 16.0, 18.4, 18.8, 20.2, 21.4, 22.5, 24.3, 26.2 and 28.6 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- crystalline Form H2 of Firibastat is isolated.
- crystalline Form H2 of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
- Crystalline Form H2 of Firibastat may be a hydrate. In embodiments, crystalline Form H2 may contain about 6 % to about 10% of water.
- Crystalline Form H2 of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 2; and combinations thereof.
- Crystalline Form H2 may be polymorphically pure.
- the present disclosure includes a crystalline polymorph of Firibastat, designated Form A.
- Crystalline Form A of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 3; an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2- theta ⁇ 0.2 degrees 2-theta; a solid state 13 C NMR spectrum having characteristic peaks at 49.9, 49.0, 46.3, 42.9, 39.5, 31.0 and 26.9 ppm ⁇ 0.2 ppm; a solid state 13 C NMR spectrum substantially as depicted in Figure 8 or in Figure 8A; and combinations of these data.
- Crystalline Form A of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 18.8, 21.7, 22.3, 26.6 and 27.2 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Crystalline Form A of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 18.8, 19.9, 21.7, 22.3, 23.4, 26.6 and 27.2 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- crystalline Form A of Firibastat is isolated. Particularly, crystalline Form A of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
- Crystalline Form A of Firibastat may be anhydrous.
- Crystalline Form A of Firibastat may be polymorphically pure.
- Crystalline Form A of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 11.2,
- Crystalline Form A may be particularly stable, e.g. thermally stable, stable to high relative humidity, stable to grinding, and/or stable to compression.
- the present disclosure includes a crystalline polymorph of Firibastat, designated Form B.
- Crystalline Form B of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 4; an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2- theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
- Crystalline Form B of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ⁇ 0.2 degrees 2- theta, and also having any one, two, three, four or five additional peaks selected from 17.6, 17.9,
- Crystalline Form B of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 17.6, 17.9, 18.5, 20.1, 22.3, 23.3, 24. land 25.5 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- crystalline Form B of Firibastat is isolated.
- crystalline Form B of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
- Crystalline Form B of Firibastat may be polymorphically pure.
- Crystalline Form B of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 4; and combinations thereof.
- Crystalline Form B may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
- Firibastat crystal Form El may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 5; an X-ray powder diffraction pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ⁇ 0.2 degrees 2-theta; a solid state 13 C NMR spectrum having characteristic peaks at 29.4, 37.9, 44.9, 47.0, and 50.3 ppm ⁇ 0.2 ppm; a solid state 13 C NMR spectrum substantially as depicted in Figure 9 or in Figure 9A; and combinations of these data.
- Crystalline Form El of Firibastat as described in any embodiment disclosed herein may be further characterized by an X-ray powder diffraction pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 22.3, 22.9, 23.3, 23.7 and 27.3 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Firibastat crystalline Form El as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 6, Procedures A, B, C or D.
- the present disclosure therefore encompasses Firibastat crystal Form El obtainable by a process according to any of Example 6, Procedures A, B, C or D.
- crystalline Form El of Firibastat is isolated.
- Firibastat crystalline Form El according to any aspect or embodiment of the disclosure may be isolated.
- Firibastat crystalline Form El may be a hydrate.
- Crystalline Form El of Firibastat may be polymorphically pure.
- Crystalline Form El of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 5; and combinations thereof.
- Crystalline Form El according to any aspect or embodiment of the disclosure may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
- the disclosure further encompasses a crystalline form of Firibastat: piperazine, designated Form PI.
- Crystalline Form PI of Firibastat: piperazine is a distinct molecular species.
- Crystalline Form PI of Firibastat: piperazine may be a co-crystal of Firibastat and piperazine.
- crystalline Form PI of Firibastat: piperazine may be a salt (Firibastat piperazinium or Firibastat piperazine salt).
- Form PI of Firibastat: piperazine is a salt.
- the molar ratio between Firibastat and piperazine is between 1: 1.5 and 1.5: 1, preferably between 1: 1.25 and 1.25: 1, about 1:2, or about 1:1, preferably about 1:2.
- Crystalline Form PI of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 6; an X-ray powder diffraction pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ⁇ 0.2 degrees 2-theta; and combinations of these data.
- Crystalline Form PI of Firibastat may be further characterized by an X- ray powder diffraction pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 15.7, 20.0, 20.7, 25.1 and 27.7 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Crystalline Form PI of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 12.5, 15.7, 16.4, 17.6, 19.5, 20.0, 20.7, 22.1, 25.1 and 27.7 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Firibastat Piperazine crystal Form PI as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 7, Procedures A, B or C.
- the present disclosure therefore encompasses Firibastat: Piperazine crystal Form PI obtainable by a process according to any of Example 7, Procedures A, B or C.
- crystalline Form PI of Firibastat: piperazine is isolated.
- Crystalline Form PI of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 6; and combinations thereof.
- Crystalline Form PI may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
- the disclosure further encompasses a crystalline phase of Firibastat: L-Proline, designated Form P2.
- Crystalline Form P2 of Firibastat: L-proline crystalline phase is a distinct molecular species.
- crystalline Firibastat: L-Proline may be a co-crystal of Firibastat and L-Proline.
- crystalline Firibastat: L-Proline may be a salt.
- the molar ratio between the active pharmaceutical ingredient (Firibastat) and the coformer (L-Proline) is between 1:3 and 3:1, preferably between 1:2.5 and 2.5:1, in other embodiments about 1:2.
- Crystalline Form P2 of Firibastat L-Proline may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 7; an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ⁇ 0.2 degrees 2-theta; a solid state 13 C NMR spectrum substantially as depicted in Figure 10; and combinations of these data.
- L-Proline may be further characterized by an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ⁇ 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 18.5, 19.0, 19.7, 21.3 and 21.9 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Firibastat L-Proline may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 18.5, 19.0, 19.7, 20.2, 21.3, 21.9 23.5 and 25.7 degrees 2-theta ⁇ 0.2 degrees 2-theta.
- Firibastat L-Proline crystal Form P2 as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 8, Procedures A or B. The present disclosure therefore encompasses Firibastat crystal Form P2 is obtainable by a process according to any of Example 8, Procedures A or B.
- crystalline Form P2 of Firibastat L-Proline is isolated.
- crystalline Form P2 of Firibastat L-proline according to any aspect or embodiment of the disclosure may be isolated.
- Crystalline Form P2 of Firibastat L-Proline may be polymorphically pure.
- Crystalline Form P2 of Firibastat L-Proline may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ⁇ 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 7; and combinations thereof.
- the crystalline forms of Firibastat described herein may comprise: no more than about 10%, no more than about 5%, no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent.
- Form A of Firibastat may comprise no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, wherein the residual solvent is preferably a C1-C6 alcohol and, particularly a C1-C3 alcohol, and more particularly ethanol. More preferably, Form A may comprise no more than about 2%, no more than about 1.5%, no more than about %, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g.
- Form B of Firibastat may comprise: no more than about 10%, no more than about 5%, no more than about 2.5%, no more about than 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, preferably wherein the residual solvent is an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid.
- the residual solvent is an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid.
- Form B may comprise no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, wherein the residual solvent is preferably a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid. More preferably, Form B may comprise no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g.
- Form B may comprise no more than 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0.5% to about 2%, or about 0.5% to about 1.5%, about 0.5 to about 1.2%, or about 0.5% to about 1%) by weight of propionic acid.
- the crystalline forms of Firibastat described herein may comprise: no more than about 40%, no more than about 35%, no more than about 30%, no more than about 25%, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g.
- a strong acid or base preferably wherein the strong acid is 1,2-ethanedi sulfonic acid, sulfuric acid, methanesulfonic acid, or p-toluenesulfonic acid, and preferably wherein the base is benzathine.
- Form A of Firibastat may comprise: no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0% to about 10%, about 0.05% to about 5%, about 0.05% to about 2%, about 0.05% to about 1.0%, or about 0.05 to about 0.2%), by weight of 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, or benzathine.
- 1,2-ethanedisulfonic acid sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, or benzathine.
- Form A may comprise no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% % (e.g.
- Form A may comprise: no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% % (e.g.
- Form El may comprise: no more than about 40%, no more than about 35%, no more than about 30%, no more than about 25%, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g.
- Form El may comprise: about 0% to about 40%, about 1% to about 35%, about 0.5% to about 35%, about 1% to about 30%, about 1.0% to about 25%, about 1% to 20%, about 1% to about 10%, about 1% to about 5%, or about 1% to about 2%), by weight of a strong acid, preferably wherein the strong acid is 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, or p-toluenesulfonic acid, and more preferably 1,2-ethanedisulfonic acid,
- Form El may comprise: about 0% to about 40%, about 1% to about 35%, about 0.5% to about 35%, about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 10%, about 1% to about 5%, or about 1% to about 2% or about 0.1% to about 2%, or about 0.1% to about 1%), by weight of 1,2-ethanedisulfonic acid.
- the above crystalline forms can be used to prepare other crystalline polymorphs of Firibastat, Firibastat salts or co-crystals and their solid state forms.
- the present disclosure encompasses a process for preparing other solid state forms of Firibastat, Firibastat salts or co-crystals and solid state forms thereof.
- the process includes preparing any one or a mixture of the above disclosed form of Firibastat by the processes of the present disclosure, and converting it to said other form of Firibastat or Firibastat salt or co crystal.
- the present disclosure includes a process for preparation of Form A of Firibastat wherein the process comprises crystallization of Firibastat in the presence of a strong acid, such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p- toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
- a strong acid such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p- toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
- the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of a strong acid, preferably a strong acid such as but not limited to: 1,2- ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
- a strong acid preferably a strong acid such as but not limited to: 1,2- ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the is dissolved in the reaction mixture
- a strong acid preferably a strong acid such as but not limited to: 1,2- ethanedisulfonic acid, sulfuric acid, methanesulf
- the reaction mixture in step (a) is performed a slurry.
- step (a) is performed in a polar solvent which is capable of dissolving the acid, or in which the acid is miscible, preferably wherein the solvent is an alcohol (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol.
- the strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat. .
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- step (c) the solvent is separated by centrifuge.
- the present disclosure includes a process for preparation of Form A wherein the process comprises crystallization of Firibastat in the presence of 1,2-ethanedisulfonic acid in a solvent or a mixture of solvents wherein 1,2-ethanedisulfonic acid is dissolved, or in the presence of Benzathine in a solvent or a mixture of solvents wherein benzathine is dissolved.
- the strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to equivalents relative to Firibastat.
- the benzathine is preferably used in an amount of: about 0.2 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, or about 0.5 to about 1.5, or about 0.6 to about 1.4 equivalents relative to Firibastat.
- the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of 1,2-ethanedisulfonic acid, wherein 1,2-ethanedisulfonic acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
- the reaction mixture in step (a) is performed a slurry.
- step (a) is performed in a polar solvent, which is capable of dissolving the 1,2- ethanedisulfonic acid preferably an alcohol (particularly a C1-C6 alcohol and more particularly a C 1 -C 3 alcohol), more preferably ethanol.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- step (c) the solvent is separated by centrifuge.
- the 1,2-ethanedisulfonic acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat.
- the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of benzathine, wherein benzathine is dissolved in the reaction mixture b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
- the reaction mixture in step (a) is performed a slurry.
- step (a) is performed in a polar solvent, which is capable of dissolving the benzathine preferably an alcohol (particularly a C 1 -C 6 alcohol and more particularly a C 1 -C 3 alcohol), more preferably ethanol.
- the benzathine is preferably used in an amount of: about 0.2 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, or about 0.5 to about 1.5, or about 0.6 to about 1.4 equivalents relative to Firibastat.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- step (c) the solvent is separated by centrifuge.
- the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form (preferably Form HI), in a solvent or mixture of solvents performed in a polar solvent, preferably alcohol (particularly a C1-C6 alcohol and more (particularly a C 1 -C 3 alcohol), more preferably ethanol) in the presence of an inorganic or organic acid (preferably a mineral acid or a carboxylic acid or a sulfonic acid, and more preferably sulfuric acid or methane sulfonic acid, or para-toluene sulfonic acid); b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
- a polar solvent preferably alcohol (particularly a C1-C6 alcohol and more (particularly a C 1 -C 3 alcohol), more preferably ethanol) in the presence of an inorganic or organic acid (preferably a mineral acid or a carboxylic acid or
- the reaction mixture in step (a) is performed a slurry.
- step (a) is performed in a polar solvent, preferably alcohol, (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol) more preferably ethanol.
- the acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to equivalents relative to Firibastat.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- step (c) the solvent is separated by centrifuge.
- the starting material may be any (preferably hydrated) form of Firibastat, such as Form HI or H2, or any mono-, di, or tri-hydrate form, including the trihydrate form disclosed in WO 2012/045849.
- the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
- the solvent is a polar solvent, and particularly a polar protic solvent, wherein the polar solvent is an alcohol, more particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol or isopropanol .
- the present disclosure includes a process for preparation of Firibastat Form B wherein the process comprises: a) providing a slurry of Firibastat in a one or more solvents comprising an acid; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form B; and d) optionally washing and/or drying Form B.
- the sole solvent in step (a) is an acid, preferably an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 carboxylic acid, and more preferably acetic acid or propionic acid.
- the process for preparing Firibastat Form B comprise crystallising Firibastat from a solvent which is a C1-C6 carboxylic acid, a C2-C5 carboxylic acid, and more preferably acetic acid or propionic acid.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 60 °C.
- step (c) the solvent is separated by centrifuge.
- the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
- the present disclosure includes a process for preparation of Firibastat Form El wherein the process comprises: a) contacting Firibastat with 1,2-ethanedisulfonic acid wherein the molar ratio of Firibastat and 1,2-ethanedisulfonic acid is about 1:1 in the presence of one or more solvents wherein 1,2- ethanedisulfonic acid is not dissolved; b) ) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Firibastat Form El; and d) optionally washing and/or drying Firibastat Form El.
- the reaction mixture in step (a) is a slurry and preferably the Firibastat provided as starting material is a hydrated form or an anhydrous form.
- the starting material in step (a) of the process for preparing Form El as described in any of the processes herein may be any form of Firibastat, such as Form HI or H2, or any mono-, di, or tri hydrate form, including the trihydrate form disclosed in WO 2012/045849, or may be Form A as described herein.
- the 1,2-ethanedisulfonic acid may be used in an amount of: about 0.2 to about 2, about 0.5 to about 1.5, about 0.6 to about 1.2, about 0.8 to about 1.2, or about 0.9 to about 1.1, or about 1 mole equivalents relative to Firibastat.
- the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
- the 1,2- ethanesdisulfonic acid is used as a dihydrate.
- the solvent in step (a) is a polar aprotic solvent, preferably ether solvents, more preferably THF, halogenated solvents, more preferably dichloromethane, or ester solvents, more preferably ethyl acetate.
- the solvents in step (a) comprises one or more aromatic solvents such as toluene.
- the reaction mixture in step (a) comprises a mixture of an aromatic solvent and an ester solvent, preferably a mixture of toluene and ethyl acetate.
- the ratio of ethyl acetate to toluene is from about 1 :6 to about 2:1, preferably from about 1 :4 to about 1:1, more preferably about 1:2.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- the solvent is separated by centrifuge.
- the present disclosure further provides a process for the preparation of Firibastat: piperazine, preferably Form PI, comprising:
- reaction mixture in step (i) is a solution.
- step (i) comprises contacting Firibastat and piperazine in water or in a mixture of solvents comprising water and step (ii) comprises removing the solvent or solvent mixture.
- the reaction mixture in step (i) is a slurry and preferably the Firibastat provided as starting material is a hydrated form.
- the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- the solvent is separated by centrifuge.
- the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C, or about 40°C to about 60°C.
- the present disclosure further provides a process for the preparation of a Firibastat: L-Proline, preferably Form P2, comprising: (i) contacting Firibastat with L-Proline in the presence of one or more solvents;
- reaction mixture in step (i) is a solution.
- step (i) comprises contacting Firibastat and L-Proline in one or more polar solvents and step (ii) comprises removing the solvent or solvent mixture.
- the reaction mixture in step (i) is a slurry.
- the Firibastat provided as starting material is a non-hydrated form.
- the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol.
- the reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
- the solvent is separated by centrifuge.
- the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 85°C, about 35°C to about 80°C or about 40°C to about 75°C.
- the molar ratio of Firibastat to L-Proline is from about 1 :4 to about 4:1, or from about 1:3 to about 3:1, or from about 1:2.5 to about 2.5:1. In embodiments the molar ratio of Firibastat to L-Proline is about 1 :2.
- the present disclosure further relates to a product obtainable by any of the processes described herein.
- Any of the above described processes may further comprise a step of combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- the present disclosure provides the above described crystalline polymorphs of Firibastat, Firibastat salts or co-crystals for use in the preparation of pharmaceutical compositions comprising Firibastat, Firibastat salts or co-crystals and/or crystalline polymorphs thereof.
- the present disclosure also encompasses the use of crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure for the preparation of pharmaceutical compositions of crystalline polymorph Firibastat, Firibastat salts or co-crystals and/or crystalline polymorphs thereof.
- the present disclosure includes processes for preparing the above mentioned pharmaceutical compositions.
- the processes include combining any one or a combination of the crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure with at least one pharmaceutically acceptable excipient.
- compositions of the present disclosure contain any one or a combination of the solid state forms of Firibastat, Firibastat salts or co-crystals of the present disclosure.
- the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
- Diluents increase the bulk of a solid pharmaceutical composition, and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle.
- Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfme cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
- microcrystalline cellulose e.g., Avicel®
- microfme cellulose lactose
- starch pregelatinized starch
- calcium carbonate calcium sulfate
- sugar dextrates
- Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
- Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g.
- Methocel® liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch.
- povidone e.g. Kollidon®, Plasdone®
- pregelatinized starch sodium alginate, and starch.
- Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac- Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g., Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
- alginic acid e.g., Ac- Di-Sol®, Primellose®
- colloidal silicon dioxide e.g., croscarmellose sodium
- crospovidone e.g., Kollidon®, Polyplasdone®
- guar gum e.g., magnesium aluminum silicate
- methyl cellulose e.g., microcrystalline cellulose
- polacrilin potassium ed
- Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing.
- Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
- a dosage form such as a tablet is made by the compaction of a powdered composition
- the composition is subjected to pressure from a punch and dye.
- Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities.
- a lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye.
- Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate.
- Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
- Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
- Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
- Firibastat, Firibastat salts or co-crystals and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
- a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin.
- Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier.
- Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
- Liquid pharmaceutical compositions of the present invention can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract.
- Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.
- Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.
- Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.
- a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
- a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate.
- the solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions.
- the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral.
- the dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
- Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs.
- the dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell.
- the shell can be made from gelatin and optionally contain a plasticizer such as glycerin and/or sorbitol, an opacifying agent and/or colorant.
- the active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.
- a composition for tableting or capsule filling can be prepared by wet granulation.
- wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules.
- the granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size.
- the granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.
- a tableting composition can be prepared conventionally by dry blending.
- the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.
- a blended composition can be compressed directly into a compacted dosage form using direct compression techniques.
- Direct compression produces a more uniform tablet without granules.
- Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
- a capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.
- Firibastat, Firibastat salts or co-crystals can be administered.
- Firibastat, Firibastat salts or co-crystals may be formulated for administration to a mammal, in embodiments to a human, by injection.
- Firibastat, Firibastat salts or co-crystals can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection.
- the formulation can contain one or more solvents.
- a suitable solvent can be selected by considering the solvent's physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity.
- Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and antioxidants, among others. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.
- Firibastat, Firibastat salts or co-crystals and the pharmaceutical compositions and/or formulations of Firibastat, Firibastat salts or co-crystals of the present disclosure can be used as medicaments, in embodiments in the treatment of hypertension.
- the present disclosure also provides methods of treating hypertension by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure, or at least one of the above pharmaceutical compositions and/or formulations, to a subject in need of the treatment.
- Form A A crystalline form, designated Form A, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ⁇ 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 3; c. a solid state 13 C NMR spectrum having characteristic peaks at 49.9, 49.0, 46.3, 42.9, 39.5, 31.0 and 26.9 ppm ⁇ 0.2 ppm; d. a solid state 13 C NMR spectrum substantially as depicted in Figure 8 or in Figure 8A; and e. combination of these data.
- a crystalline product according to Clause Al designated Form A, characterized by the XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ⁇ 0.2 degrees 2- theta, and also having one, two, three or four additional peaks selected from 18.8, 21.7, 22.3,
- a crystalline form designated Form A, according to any one of Clauses A1 or A2 wherein the form is anhydrous.
- a crystalline product according to any one of Clauses A1-A3 designated Form A which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
- a process for preparation of Form A according to any one of clauses A1-A5, wherein the process comprises crystallization of Firibastat in the presence of 1,2-ethanedisulfonic acid in a solvent or a mixture of solvents wherein 1,2-ethanedisulfonic acid is dissolved, or in the presence of Benzathine in a solvent or a mixture of solvents wherein benzathine is dissolved.
- a process according to clause A6 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of 1,2-ethanedisulfonic acid, wherein 1,2-ethanedisulfonic acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
- a process for preparation of Form A according to any one of clauses A1-A5, wherein the process comprises crystallization of Firibastat in the presence of a strong acid, such as, but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
- a strong acid such as, but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
- a process according to clause A8 wherein the process comprises: a) providing Firibastat, in a solvent or mixture of solvents in the presence of a strong acid, preferably a strong acid such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
- a strong acid preferably a strong acid such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the acid is dissolved in the reaction mixture
- a strong acid such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-
- a process according to clause A8 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form in a solvent or mixture of solvents performed in the presence of an inorganic or organic acid (preferably a mineral acid or a carboxylic acid or a sulfonic acid, and more preferably sulfuric acid or methane sulfonic acid or para-toluene sulfonic acid, wherein the acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
- an inorganic or organic acid preferably a mineral acid or a carboxylic acid or a sulfonic acid, and more preferably sulfuric acid or methane sulfonic acid or para-toluene sulfonic acid, wherein the acid is dissolved in the reaction mixture
- an inorganic or organic acid preferably a mineral acid or a carboxylic
- a process according to Clause A7, A9 or A10 wherein the reaction mixture is step (a) is a slurry.
- step (a) is performed in a polar solvent which is capable of dissolving the acid, or in which the acid is miscible, preferably alcohol, particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol, more preferably ethanol.
- a polar solvent which is capable of dissolving the acid, or in which the acid is miscible, preferably alcohol, particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol, more preferably ethanol.
- A13 A process according to any one of clauses A7-A12 wherein the strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat
- A14 A process according to any one of Clauses A7-A13 wherein the reaction mixture is heated to temperature of from about 30 °C to about 50 °C.
- A15 A process according to any one of Clauses A7-A14 wherein in step (c) the solvent is separated by centrifuge.
- A16 A process according to clause A6 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of benzathine, wherein benzathine is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
- a process according to Clause A16 wherein the reaction mixture is step (a) is a slurry.
- step (a) is performed in a polar solvent, which is capable of dissolving benzathine, or in which benzathine is miscible, preferably alcohol, (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol)more preferably ethanol.
- a polar solvent which is capable of dissolving benzathine, or in which benzathine is miscible, preferably alcohol, (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol)more preferably ethanol.
- A20 A process according to any one of Clauses A16-A19 wherein the reaction mixture is heated to temperature of from about 30 °C to about 50 °C.
- step (c) A process according to any one of Clauses A16-A20 wherein in step (c) the solvent is separated by centrifuge.
- a process according to any one of Clauses A6-A21 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- a crystalline product obtainable by a process according to any one of Claims A6-A20.
- a pharmaceutical composition comprising a crystalline product according to any of Clauses A1-A5 or A23, and at least one pharmaceutically acceptable excipient.
- A25 Use of a crystalline product according to any of Clauses A1-A5 or A23 for the preparation of a pharmaceutical composition and/or formulation.
- A26. A process for preparing the pharmaceutical composition according to Clause A24, comprising combining a crystalline product according to any of Clauses A1-A5 or A23 with at least one pharmaceutically acceptable excipient.
- a method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses A1-A5 or A23, or a pharmaceutical composition according to Clause A24, to a subject in need of the treatment.
- a process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Al- A5 or A23, and converting it to another a solid state form thereof or Firibastat salt.
- Form B A crystalline form, designated Form B, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ⁇ 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 4; and c. combination of these data.
- a crystalline product according to any one of Clauses B1-B2 designated Form B which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
- step (a) is an acid, preferably an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid.
- step (c) the solvent is separated by centrifuge.
- a process according to any one of Clauses B5-B8 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- a pharmaceutical composition comprising a crystalline product according to any of Clauses B1-B4 or B10, and at least one pharmaceutically acceptable excipient.
- B13 A process for preparing the pharmaceutical composition according to Clause B11, comprising combining a crystalline product according to any of Clauses B1-B4 or B10 with at least one pharmaceutically acceptable excipient.
- B14 A crystalline product according to any of Clauses B1-B4 or BIO, or a pharmaceutical composition according to Clause B 12, for use as a medicament.
- a method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses B1-B4 or BIO, or a pharmaceutical composition according to Clause B11, to a subject in need of the treatment.
- a process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Bl- B4 or BIO, and converting it to another a solid state form thereof or Firibastat salt.
- Crystalline Firibastat piperazine.
- Crystalline Firibastat piperazine which is a co-crystal.
- Crystalline Firibastat piperazinium which is a salt (i.e. Firibastat piperazine salt), optionally wherein the ratio of Firibastat to piperazine is about 1: 1.5 to about 1.5: 1, preferably between about 1: 1.25 and about 1.25: 1, about 1:2 or about 1:1, and preferably about 1:2.
- step (i) comprises contacting Firibastat and piperazine in water or in a mixture of solvents comprising water and step (ii) comprises removing the solvent or solvent mixture.
- step (ii) the solvent is separated by centrifuge.
- a process according to any one of Clauses C8-C15 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- a pharmaceutical composition comprising a crystalline product according to any of Clauses C1-C7 or Cl 7, and at least one pharmaceutically acceptable excipient.
- a method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses C1-C7 or Cl 7, or a pharmaceutical composition according to Clause Cl 8, to a subject in need of the treatment.
- a process for preparing a solid state form of Firibastat piperazine or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses C1-C7 or Cl 7, and converting it to another a solid state form thereof or Firibastat salt.
- a crystalline Firibastat designated Form El which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2- theta ⁇ 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 5; c. a solid state 13 C NMR spectrum having characteristic peaks at 29.4, 37.9, 44.9, 47.0, and 50.3 ppm ⁇ 0.2 ppm; d. a solid state 13 C NMR spectrum substantially as depicted in Figure 9 or in Figure 9A; and e. combinations of these data.
- a crystalline product according to any of Clauses D1-D3, designated Form El which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat
- the solvent comprises one or more polar aprotic solvents, preferably ether solvents, more preferably THF, halogenated solvents, more preferably dichloromethane or ester solvents, more preferably ethyl acetate.
- step (c) A process according to any one of Clauses D6-D11 wherein in step (c) the solvent is separated by centrifuge.
- a process according to any of Clauses D6-D12 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
- a pharmaceutical composition comprising a crystalline product according to any of Clauses D1-D5 or D14, and at least one pharmaceutically acceptable excipient.
- a process for preparing the pharmaceutical composition according to Clause D15 comprising combining a crystalline product according to any of Clauses D1-D5 or D14 with at least one pharmaceutically acceptable excipient.
- a method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses D1-D5 or D 14, or a pharmaceutical composition according to Clause D 15, to a subject in need of the treatment.
- a process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Dl- D5 or D14, and converting it to another a solid state form thereof or Firibastat salt.
- Crystalline Firibastat L-Proline which is a co-crystal.
- step (i) comprises contacting Firibastat and L-Proline in one or more Polar solvents and step (ii) comprises removing the solvent or solvent mixture.
- step (ii) A process according to any one of clauses E8, Ell, E12, E13 or E14 wherein in step (ii) the solvent is separated by centrifuge.
- a pharmaceutical composition comprising a crystalline product according to any of Clauses E1-E7 or E18, and at least one pharmaceutically acceptable excipient.
- a process for preparing the pharmaceutical composition according to Clause El 9, comprising combining a crystalline product according to any of Clauses E1-E7 or E18 with at least one pharmaceutically acceptable excipient.
- a method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses E1-E7 or El 8, or a pharmaceutical composition according to Clause El 9, to a subject in need of the treatment.
- a process for preparing a solid state form of Firibastat: L-Proline or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses E1-E7 or E18, and converting it to another a solid state form thereof or Firibastat salt.
- XRPD analysis was performed on Bruker powder X-Ray diffractometer model D8 ADVANCE equipped with a solid state detector. Copper radiation of 1.54060 A was used. Scanning parameters: range: 2-40 degrees two-theta; scan mode; step size: 0.05°.
- Firibastat can be prepared according to methods known from the literature, for example as described in International Publication No. WO 2004/007441.
- Ethanol (6 ml, 20V) was added to Firibastat (300 mg, 0.81 mmol, prepared according to example 3, procedure A, and 1,2-Ethanedisulfonic acid dihydrate (72 mg, 0.3 mmol) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 72 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml).
- the wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A and the XRPD pattern is presented in Figure 3.
- Ethanol (3 ml, 10V) was added to Firibastat (300 mg, 0.81 mmol, prepared according to example 3, procedure A) and Benzathine (0.2 ml, 0.83 mmol) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 24 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml).
- the white wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
- Ethanol (1 ml, 10V) was added to Firibastat (100 mg, 0.21 mmol, prepared according to example 3, procedure A) and Benzathine (0.03 ml, 0.13 mmol) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 72 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml).
- the wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
- Ethanol (1 ml, 10V) was added to Firibastat (100 mg, 0.21 mmol, prepared according to example 1) and Benzathine (0.07 ml, 0.26 mmol) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 24 hours, then was cooled to room temperature and was separated by centrifuge.
- the wet solid was dried in a vacuum oven at 40°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
- Ethanol 50 ml, 20V was added to Firibastat (2.5 grams, 6.8 mmol), prepared according to example 2, procedure B, and 1,2-Ethanedisulfonic acid dihydrate (600 mg, 2.5 mmol) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and stirred for 120 hours.
- the solid was separated by Buchner followed by washing with Ethanol (3*7.5 ml).
- the wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A.
- Ethanol (1 ml, 20V) was added to Firibastat (57 mg, 0.15 mmol), prepared according to example 2, procedure B, and 98% FbSCri (29 m ⁇ ) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C over a period of 48 hours. Then, the solid was separated by centrifuge. The wet solid was characterized by X-ray powder diffraction as Firibastat crystal Form A.
- Ethanol (11.4 ml, 20V) was added to Firibastat (570 mg, 1.5 mmol), prepared according to example 2, procedure B, and 98% FbSCE (298 m ⁇ ) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C over a period of 72 hours. Then, the solid was separated by centrifuge. The wet solid was suspended in Ethanol (11.4 ml, 20V) to obtain slurry and 98% H 2 SO 4 (298 m ⁇ ) was added.
- the slurry was magnetically stirred and heated to 40°C over a period of 48 hours. Then, the solid was separated by centrifuge and dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A.
- Ethanol (1 ml, 20V) was added to Firibastat (57 mg, 0.15 mmol), prepared according to example 2, procedure B, and Methansulfonic acid (17.6 m ⁇ ) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C over a period of 16 hours. Then, the solid was separated by centrifuge. The wet solid was characterized by X-ray powder diffraction as Firibastat crystal Form A.
- Acetic acid (4 ml, 20V) was added to Firibastat (200 mg, 0.54 mmol, prepared according to example 3, procedure A) to obtain a slurry.
- the slurry was magnetically stirred and heated to 60°C.
- the slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge.
- the wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form B and the XRPD pattern is presented in Figure 4.
- Acetic acid (1 ml, 20V) was added to Firibastat (50 mg, 0.13 mmol, prepared according to example 1) to obtain a slurry.
- the slurry was magnetically stirred and heated to 60°C.
- the slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge.
- the wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form B.
- Ethyl acetate (11 ml, 20V) was added to Firibastat (536.5 mg, 1.35 mmol, prepared according to example 3, procedure A) and 1,2-Ethanedisulfonic acid dihydrate (298 mg, 1.35 mmol, 1:1 eq) to obtain a slurry.
- the slurry was magnetically stirred and heated to 40°C.
- the slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge.
- the wet solid and dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form El.
- Isopropyl alcohol (4.67 ml, 10V) was added to piperazine (467.5 mg, 5.4 mmol) to obtain clear solution. Then, Firibastat (1000 mg, 2.7 mmol, prepared according to example 2, procedure B) was added to the clear solution of piperazine in IPA to obtain slurry. Additional portion of 5.32 ml of isopropyl alcohol was added to the stirred slurry. The slurry was then heated to 40°C and stirred at 40°C for 16 hours. The obtained wet solid was separated by centrifuge and washed twice with 2 ml IPA.
- Firibastat Piperazine crystal Form PI.
- Example 8 Preparation of Firibastat: L-Proline Form P2 Procedure A
- Firibastat Form A that can be prepared according to example 4, procedure A
- L-Proline 400 mg was added to the slurry.
- the slurry was then heated to 40°C and stirred at 40°C for 48 hours.
- the obtained wet solid was separated by centrifuge and was dried in a vacuum oven at 45 °C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat: L-Proline crystal Form P2 and the XRPD pattern is presented in Figure 7.
Abstract
The present disclosure encompasses solid state forms of Firibastat and salts or co-crystals thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
Description
SOLID STATE FORMS OF FIRIBASTAT AND PROCESSES FOR PREPARATION THEREOF
FIELD OF THE DISCLOSURE
[0001] The present disclosure encompasses solid state forms of Firibastat and salts or co crystals thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
BACKGROUND OF THE DISCLOSURE
[0002] Firibastat, (Sri^AFd^-DithiobisP-amino-l-butanesulfonic acid], has the following chemical structure:
[0003] Firibastat is a prodrug of the APA inhibitor EC33, an inhibitor of aminopeptidase A, and it is developed for the treatment of hypertension.
[0004] The compound is described in International Publication No. WO 2004/007441. Crystalline Firibastat is disclosed in International Publication No. WO 2012/045849 and a crystalline phase of Firibastat with L-lysine is disclosed in International Publication No. WO 2014/064077.
[0005] Polymorphism, the occurrence of different crystalline forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis (“TGA”), or differential scanning calorimetry (“DSC”)), X-ray diffraction (XRD) pattern, infrared absorption fingerprint, and solid state (13C) NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound.
[0006] Different salts and solid state forms (including solvated forms) of an active pharmaceutical ingredient may possess different properties. Such variations in the properties of different salts and solid state forms and solvates may provide a basis for improving formulation, for example, by facilitating better processing or handling characteristics, changing the dissolution profile in a favorable direction, or improving stability (polymorph as well as
chemical stability) and shelf-life. These variations in the properties of different salts and solid state forms may also offer improvements to the final dosage form, for instance, if they serve to improve bioavailability. Different salts and solid state forms and solvates of an active pharmaceutical ingredient may also give rise to a variety of polymorphs or crystalline forms, which may in turn provide additional opportunities to assess variations in the properties and characteristics of a solid active pharmaceutical ingredient.
[0007] Discovering new solid state forms and solvates of a pharmaceutical product may yield materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms. New solid state forms of a pharmaceutically useful compound can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, including a different crystal habit, higher crystallinity, or polymorphic stability, which may offer better processing or handling characteristics, improved dissolution profile, or improved shelf-life (chemical/physical stability). For at least these reasons, there is a need for additional solid state forms (including solvated forms) of Firibastat.
SUMMARY OF THE DISCLOSURE
[0008] The present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat; processes for preparation thereof, and pharmaceutical compositions thereof. These crystalline polymorphs and crystalline salts and co-crystals can be used to prepare other solid state forms of Firibastat, Firibastat co-crystals, Firibastat salts and their solid state forms.
[0009] The present disclosure also provides uses of the said solid state forms of Firibastat, Firibastat co-crystals and/or Firibastat salts in the preparation of other solid state forms of Firibastat or Firibastat co-crystals or salts thereof.
[0010] The present disclosure also provides the said solid state forms of Firibastat, Firibastat, co-crystals and/or Firibastat salts for use in the preparation of other solid state forms of Firibastat, or Firibastat, co-crystals or salts thereof.
[0011] The present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat for use in the preparation of pharmaceutical compositions and/or formulations for use in medicine, including for the treatment of hypertension.
[0012] The present disclosure also encompasses the use of crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure for the preparation of pharmaceutical compositions and/or formulations.
[0013] In another aspect, the present disclosure provides pharmaceutical compositions including crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts according to the present disclosure.
[0014] In yet another embodiment, the present disclosure encompasses pharmaceutical formulations including any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts or pharmaceutical compositions including the described crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts and at least one pharmaceutically acceptable excipient.
[0015] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts with at least one pharmaceutically acceptable excipient.
[0016] The crystalline polymorphs of Firibastat, as well as co-crystals and/or salts of Firibastat as defined herein and the pharmaceutical compositions or formulations of the crystalline polymorph of Firibastat, Firibastat co-crystals and/or Firibastat salts may be used as medicaments, such as for the treatment of hypertension.
[0017] The present disclosure also provides methods of treating hypertension, by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure, or at least one of the above pharmaceutical compositions, to a subject suffering from hypertension, or otherwise in need of the treatment.
[0018] The present disclosure also provides uses of crystalline polymorphs of Firibastat, Firibastat co-crystals and/or Firibastat salts of the present disclosure, or at least one of the above pharmaceutical compositions, for the manufacture of medicaments for treating e.g., hypertension.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form HI;
[0020] Figure 2 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form H2;
[0021] Figure 3 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form A;
[0022] Figure 4 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat Form B;
[0023] Figure 5 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat crystal Form El;
[0024] Figure 6 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat: piperazine Form PI;
[0025] Figure 7 shows a characteristic X-ray powder diffraction pattern (XRPD) of Firibastat: L-proline Form P2;
[0026] Figure 8 shows a characteristic solid state 13C-NMR of Firibastat Form A (200-0 ppm);
[0027] Figure 8A shows a characteristic solid state 13C-NMR of Firibastat Form A (100-0 ppm);
[0028] Figure 9 shows a characteristic solid state 13C-NMR of Firibastat crystal Form El (200-0 ppm); and
[0029] Figure 9 A shows a characteristic solid state 13C-NMR of Firibastat crystal Form EIQOO-O ppm).
DETAILED DESCRIPTION OF THE DISCLOSURE
[0030] The present disclosure provides crystalline polymorphs of Firibastat, as well as co crystals and/or salts of Firibastat; processes for preparation thereof, and pharmaceutical compositions thereof.
[0031] Solid state properties of Firibastat and crystalline polymorphs thereof can be influenced by controlling the conditions under which Firibastat and crystalline polymorphs thereof are obtained in solid form.
[0032] A solid state form (or polymorph) may be referred to herein as polymorphically pure or as substantially free of any other solid state (or polymorphic) forms. As used herein in this context, the expression "substantially free of any other forms" will be understood to mean that the solid state form contains about 20% (w/w) or less, about 10% (w/w) or less, about 5% (w/w) or less, about 2% (w/w) or less, about 1% (w/w) or less, or about 0% of any other forms of the subject compound as measured, for example, by XRPD. Thus, a crystalline polymorph of Firibastat described herein as substantially free of any other solid state forms would be understood to contain greater than about 80% (w/w), greater than about 90% (w/w), greater than about 95% (w/w), greater than about 98% (w/w), greater than about 99% (w/w), or about 100% of the subject crystalline polymorph of Firibastat In some embodiments of the disclosure, the described crystalline polymorph of Firibastat may contain from about 1% to about 20% (w/w), from about 5% to about 20% (w/w), or from about 5% to about 10% (w/w) of one or more other crystalline polymorph of the same Firibastat.
[0033] Depending on which other crystalline polymorphs a comparison is made, the crystalline polymorphs of Firibastat of the present disclosure may have advantageous properties selected from at least one of the following: chemical purity, flowability, solubility, dissolution rate, morphology or crystal habit, stability, such as chemical stability as well as thermal and mechanical stability with respect to polymorphic conversion, stability towards dehydration and/or storage stability, low content of residual solvent, a lower degree of hygroscopicity, flowability, and advantageous processing and handling characteristics such as compressibility and bulk density. Particularly, the crystalline polymorph as described in any aspect or embodiment of the present disclosure may be stable, for example to conditions of high relative humidity, and/or may be thermally stable. Crystalline Forms A, B, El, PI and P2 as described in any aspect or embodiment of the present disclosure, may be especially stable to conditions of high relative humidity and/or may be thermally stable.
[0034] A solid state form, such as a crystal form or an amorphous form, may be referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure. Such data include, for example, powder X-ray diffractograms and solid state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone. In any
event, the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and confirm whether the two sets of graphical data are characterizing the same crystal form or two different crystal forms. A crystal form of Firibastat referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of Firibastat characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure.
[0035] As used herein, and unless stated otherwise, the term “anhydrous” in relation to crystalline forms of Firibastat, relates to a crystalline form of Firibastat which does not include any crystalline water (or other solvents) in a defined, stoichiometric amount within the crystal. Moreover, an “anhydrous” form would generally not contain more than 1% (w/w), of either water or organic solvents as measured for example by TGA.
[0036] The term "solvate," as used herein and unless indicated otherwise, refers to a crystal form that incorporates a solvent in the crystal structure. When the solvent is water, the solvate is often referred to as a "hydrate." The solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
[0037] "Co-Crystal" or "Co-crystal" as used herein is defined as a crystalline material including two or more molecules in the same crystalline lattice and associated by non-ionic and non-covalent bonds. In some embodiments, the co-crystal includes two molecules which are in natural state.
[0038] As used herein, crystalline Firibastat: piperazine is a distinct molecular species Crystalline Firibastat: piperazine may be a co-crystal of Firibastat and piperazine. Alternatively crystalline Firibastat: piperazine may be a salt (Firibastat piperazinium). Preferably, Firibastat: piperazine is a salt. In embodiments the molar ratio between Firibastat and piperazine is between 1: 1.5 and 1.5: 1, preferably between 1: 1.25 and 1.25: 1, about 1:2 or in other embodiments about 1:1, and preferably about 1:2.
[0039] As used herein, crystalline Firibastat: L-Proline is a distinct molecular species and/or a distinct crystalline phase. Crystalline Firibastat: L-Proline may be a co-crystal of Firibastat and L-Proline. Alternatively, crystalline Firibastat: L-Proline may be a salt. In embodiments the molar ratio between the active pharmaceutical ingredient (Firibastat) and the coformer (L- Proline) is between 1:3 and 3:1, preferably between 1:2.5 and 2.5:1, in other embodiments about 1:2.
[0040] As used herein, the term "isolated" in reference to crystalline polymorph of Firibastat, of the present disclosure corresponds to a crystalline polymorph of Firibastat that is physically separated from the reaction mixture in which it is formed.
[0041] As used herein, unless stated otherwise, the XRPD measurements are taken using copper Kal radiation wavelength 1.54060 A. XRPD peaks reported herein are measured using CuK al radiation, l = 1.54060 A, typically at a temperature of 25 ± 3°C.
[0042] As used herein, unless stated otherwise, 13C NMR reported herein are measured at 11.7 T at a magic angle spinning frequency wG/2p = 18 kHz, preferably at a temperature of at 293 K ± 3°C.
[0043] A thing, e.g., a reaction mixture, may be characterized herein as being at, or allowed to come to “room temperature” or “ambient temperature,” often abbreviated as “RT.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
[0044] The amount of solvent employed in a chemical process, e.g., a reaction or crystallization, may be referred to herein as a number of “volumes” or “vol” or “V.” For example, a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a solvent. In this context, this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending a 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent. In another context, the term "v/v" may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v/v) to a 100 ml reaction mixture would indicate that 150 mL of solvent X was added.
[0045] A process or step may be referred to herein as being carried out "overnight." This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is from about 8 to about 20 hours, or about 10-18 hours, in some cases about 16 hours.
[0046] As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, reduced pressure is about 10 mbar to about 50 mbar.
[0047] As used herein and unless indicated otherwise, the term "ambient conditions" refer to atmospheric pressure and a temperature of 22-24°C.
[0048] The present disclosure includes a crystalline polymorph of Firibastat, designated Form HI. Crystalline Form HI of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 1; an X-ray powder diffraction pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.
[0049] Crystalline Form HI of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 18.0, 20.4, 21.9, 23.2 and 26.2 degrees 2-theta ± 0.2 degrees 2-theta.
[0050] Crystalline Form HI of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 17.8, 18.0, 18.6, 19.6, 20.4, 21.7, 21.9, 23.2, 24.4 and 26.2 degrees 2-theta ± 0.2 degrees 2-theta.
[0051] In embodiments of the present disclosure, crystalline Form HI of Firibastat is isolated. Particularly, crystalline Form HI of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
[0052] Crystalline Form HI of Firibastat may be a hydrate. In embodiments, crystalline Form HI may contain about 0.5 % to about 5 % of water.
[0053] Crystalline Form HI may be polymorphically pure.
[0054] Crystalline Form HI of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 17.8, 18.6, 19.6, 21.7 and 24.4 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 1; and combinations thereof.
[0055] The present disclosure includes a crystalline polymorph of Firibastat, designated Form H2. Crystalline Form H2 of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 2; an X-ray powder diffraction pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.
[0056] Crystalline Form H2 of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 14.5, 20.2, 21.4, 22.5 and 28.6 degrees 2-theta ± 0.2 degrees 2-theta.
[0057] Crystalline Form HI of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 14.5, 16.0, 18.4, 18.8, 20.2, 21.4, 22.5, 24.3, 26.2 and 28.6 degrees 2-theta ± 0.2 degrees 2-theta.
[0058] In embodiments of the present disclosure, crystalline Form H2 of Firibastat is isolated. Particularly, crystalline Form H2 of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
[0059] Crystalline Form H2 of Firibastat may be a hydrate. In embodiments, crystalline Form H2 may contain about 6 % to about 10% of water.
[0060] Crystalline Form H2 of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 16.0, 18.4, 18.8, 24.3 and 26.2 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 2; and combinations thereof.
[0061] Crystalline Form H2 may be polymorphically pure.
[0062] The present disclosure includes a crystalline polymorph of Firibastat, designated Form A. Crystalline Form A of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 3; an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2- theta ± 0.2 degrees 2-theta; a solid state 13C NMR spectrum having characteristic peaks at 49.9, 49.0, 46.3, 42.9, 39.5, 31.0 and 26.9 ppm ± 0.2 ppm; a solid state 13C NMR spectrum substantially as depicted in Figure 8 or in Figure 8A; and combinations of these data.
[0063] Crystalline Form A of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ± 0.2 degrees
2-theta, and also having any one, two, three, four or five additional peaks selected from 18.8, 21.7, 22.3, 26.6 and 27.2 degrees 2-theta ± 0.2 degrees 2-theta.
[0064] Crystalline Form A of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 11.2, 16.3, 17.8, 18.8, 19.9, 21.7, 22.3, 23.4, 26.6 and 27.2 degrees 2-theta ± 0.2 degrees 2-theta.
[0065] In embodiments of the present disclosure, crystalline Form A of Firibastat is isolated. Particularly, crystalline Form A of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
[0066] Crystalline Form A of Firibastat may be anhydrous.
[0067] Crystalline Form A of Firibastat may be polymorphically pure.
[0068] Crystalline Form A of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 11.2,
16.3, 17.8, 19.9 and 23.4 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 3; and combinations thereof.
[0069] Crystalline Form A according to any aspect or embodiment of the disclosure may be particularly stable, e.g. thermally stable, stable to high relative humidity, stable to grinding, and/or stable to compression.
[0070] The present disclosure includes a crystalline polymorph of Firibastat, designated Form B. Crystalline Form B of Firibastat may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 4; an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2- theta ± 0.2 degrees 2-theta; and combinations of these data.
[0071] Crystalline Form B of Firibastat may be further characterized by an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ± 0.2 degrees 2- theta, and also having any one, two, three, four or five additional peaks selected from 17.6, 17.9,
22.3, 24.1 and 25.5 degrees 2-theta ± 0.2 degrees 2-theta.
[0072] Crystalline Form B of Firibastat may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 9.4, 13.3, 17.6, 17.9, 18.5, 20.1, 22.3, 23.3, 24. land 25.5 degrees 2-theta ± 0.2 degrees 2-theta.
[0073] In embodiments of the present disclosure, crystalline Form B of Firibastat is isolated. Particularly, crystalline Form B of Firibastat according to any aspect or embodiment of the disclosure may be isolated.
[0074] Crystalline Form B of Firibastat may be polymorphically pure.
[0075] Crystalline Form B of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 4; and combinations thereof.
[0076] Crystalline Form B according to any aspect or embodiment of the disclosure may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
[0077] The disclosure further encompasses a crystalline form of Firibastat designated Form El. Firibastat crystal Form El may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 5; an X-ray powder diffraction pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ± 0.2 degrees 2-theta; a solid state 13C NMR spectrum having characteristic peaks at 29.4, 37.9, 44.9, 47.0, and 50.3 ppm ± 0.2 ppm; a solid state 13C NMR spectrum substantially as depicted in Figure 9 or in Figure 9A; and combinations of these data.
[0078] Crystalline Form El of Firibastat as described in any embodiment disclosed herein may be further characterized by an X-ray powder diffraction pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 22.3, 22.9, 23.3, 23.7 and 27.3 degrees 2-theta ± 0.2 degrees 2-theta.
[0079] Firibastat crystalline Form El as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 6, Procedures A, B, C or D. The present disclosure therefore encompasses Firibastat crystal Form El obtainable by a process according to any of Example 6, Procedures A, B, C or D.
[0080] In embodiments of the present disclosure, crystalline Form El of Firibastat is isolated. Particularly, Firibastat crystalline Form El according to any aspect or embodiment of the disclosure may be isolated.
[0081] Firibastat crystalline Form El may be a hydrate.
[0082] Crystalline Form El of Firibastat may be polymorphically pure.
[0083] Crystalline Form El of Firibastat may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 5; and combinations thereof.
[0084] Crystalline Form El according to any aspect or embodiment of the disclosure may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
[0085] The disclosure further encompasses a crystalline form of Firibastat: piperazine, designated Form PI. Crystalline Form PI of Firibastat: piperazine is a distinct molecular species. Crystalline Form PI of Firibastat: piperazine may be a co-crystal of Firibastat and piperazine. Alternatively crystalline Form PI of Firibastat: piperazine may be a salt (Firibastat piperazinium or Firibastat piperazine salt). Preferably, Form PI of Firibastat: piperazine is a salt. In embodiments the molar ratio between Firibastat and piperazine is between 1: 1.5 and 1.5: 1, preferably between 1: 1.25 and 1.25: 1, about 1:2, or about 1:1, preferably about 1:2.
[0086] Crystalline Form PI of Firibastat: piperazine may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 6; an X-ray powder diffraction pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta; and combinations of these data.
[0087] Crystalline Form PI of Firibastat: piperazine may be further characterized by an X- ray powder diffraction pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 15.7, 20.0, 20.7, 25.1 and 27.7 degrees 2-theta ± 0.2 degrees 2-theta.
[0088] Crystalline Form PI of Firibastat: piperazine may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 12.5, 15.7, 16.4, 17.6, 19.5, 20.0, 20.7, 22.1, 25.1 and 27.7 degrees 2-theta ± 0.2 degrees 2-theta.
[0089] Firibastat: Piperazine crystal Form PI as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 7, Procedures A, B or C. The present disclosure therefore encompasses Firibastat: Piperazine crystal Form PI obtainable by a process according to any of Example 7, Procedures A, B or C.
[0090] In embodiments of the present disclosure, crystalline Form PI of Firibastat: piperazine is isolated. Particularly, crystalline Form PI of Firibastat: piperazine according to any aspect or embodiment of the disclosure may be isolated.
[0091] Crystalline Form PI of Firibastat: piperazine may be polymorphically pure.
[0092] Crystalline Form PI of Firibastat: piperazine may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 6; and combinations thereof.
[0093] Crystalline Form PI according to any aspect or embodiment of the disclosure may be particularly stable, e.g. stable to high relative humidity, stable to grinding, and/or stable to compression.
[0094] The disclosure further encompasses a crystalline phase of Firibastat: L-Proline, designated Form P2. Crystalline Form P2 of Firibastat: L-proline crystalline phase is a distinct molecular species. In embodiments crystalline Firibastat: L-Proline may be a co-crystal of Firibastat and L-Proline. Alternatively, crystalline Firibastat: L-Proline may be a salt. In embodiments the molar ratio between the active pharmaceutical ingredient (Firibastat) and the coformer (L-Proline) is between 1:3 and 3:1, preferably between 1:2.5 and 2.5:1, in other embodiments about 1:2.
[0095] Crystalline Form P2 of Firibastat: L-Proline may be characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in Figure 7; an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ± 0.2 degrees 2-theta; a solid state 13C NMR spectrum substantially as depicted in Figure 10; and combinations of these data.
[0096] Crystalline Form P2 of Firibastat: L-Proline may be further characterized by an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ± 0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 18.5, 19.0, 19.7, 21.3 and 21.9 degrees 2-theta ± 0.2 degrees 2-theta.
[0097] Crystalline Form P2 of Firibastat: L-proline may be alternatively characterized by an X-ray powder diffraction pattern having peaks at 12.9, 17.8, 18.5, 19.0, 19.7, 20.2, 21.3, 21.9 23.5 and 25.7 degrees 2-theta ± 0.2 degrees 2-theta.
[0098] Firibastat: L-Proline crystal Form P2 as described in any aspect or embodiment of the present disclosure is obtainable by a process according to any of Example 8, Procedures A or B. The present disclosure therefore encompasses Firibastat crystal Form P2 is obtainable by a process according to any of Example 8, Procedures A or B.
[0099] In embodiments of the present disclosure, crystalline Form P2 of Firibastat: L-Proline is isolated. Particularly, crystalline Form P2 of Firibastat: L-proline according to any aspect or embodiment of the disclosure may be isolated.
[00100] Crystalline Form P2 of Firibastat: L-Proline may be polymorphically pure.
[00101] Crystalline Form P2 of Firibastat: L-Proline may be characterized by each of the above characteristics alone or by all possible combinations, e.g., an XRPD pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ± 0.2 degrees 2-theta; an XRPD pattern as depicted in Figure 7; and combinations thereof.
[00102] According to any aspect or embodiment of the present disclosure, the crystalline forms of Firibastat described herein (in particular Form A, Form B, Form El, and/or Form PI) may comprise: no more than about 10%, no more than about 5%, no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent. In particular, Form A of Firibastat may comprise no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, wherein the residual solvent is preferably a C1-C6 alcohol and, particularly a C1-C3 alcohol, and more particularly ethanol. More preferably, Form A may comprise no more than about 2%, no more than about 1.5%, no more than about %, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0.2% to about 1.5%, or about 0.2% to about 1.0%, or about 0.2% to about 0.8%, or about 0.2% to about 0.5%), by weight of ethanol. In particular, Form B of Firibastat may comprise: no more than about 10%, no more than about 5%, no more than about 2.5%, no more about than 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, preferably wherein the residual solvent is an organic acid, particularly
a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid. In particular, Form B may comprise no more than about 2.5%, no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05%, by weight of residual solvent, wherein the residual solvent is preferably a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid. More preferably, Form B may comprise no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0.5% to about 2%, or about 0.5% to about 1.5%, or about 0.5% to about 1.2%), by weight of acetic acid, or Form B may comprise no more than 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0.5% to about 2%, or about 0.5% to about 1.5%, about 0.5 to about 1.2%, or about 0.5% to about 1%) by weight of propionic acid.
[00103] According to any aspect or embodiment of the present disclosure, the crystalline forms of Firibastat described herein (in particular Form A and Form El), and Form PI may comprise: no more than about 40%, no more than about 35%, no more than about 30%, no more than about 25%, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0.1% to about 40%, about 0.1% to about 35%, about 0.1% to about 5%, about 0.1% to about 1.0%, or about 0.1 to about 0.5%), by weight of a strong acid or base, preferably wherein the strong acid is 1,2-ethanedi sulfonic acid, sulfuric acid, methanesulfonic acid, or p-toluenesulfonic acid, and preferably wherein the base is benzathine. In particular, Form A of Firibastat may comprise: no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0% to about 10%, about 0.05% to about 5%, about 0.05% to about 2%, about 0.05% to about 1.0%, or about 0.05 to about 0.2%), by weight of 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, or benzathine. More preferably, Form A may comprise no more than about 2%, no more than about 1.5%, no more
than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% % (e.g. about 0% to about 2%, about 0.05% to about 2%, about 0.05% to about 1.0%, or about 0.05 to about 0.2%), by weight of 1,2- ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, or p-toluenesulfonic acid,; or Form A may comprise: no more than about 2%, no more than about 1.5%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% % (e.g. about 0% to about 2%, about 0.05% to about 2%, about 0.05% to about 1.0%, or about 0.05 to about 0.2%), by weight of benzathine. In particular Form El may comprise: no more than about 40%, no more than about 35%, no more than about 30%, no more than about 25%, no more than about 20%, no more than about 15%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1%, no more than about 0.5%, no more than about 0.25%, no more than about 0.2%, no more than about 0.1%, or no more than about 0.05% (e.g. about 0% to about 40%, about 0.1% to about 35%, about 0.5% to about 35%, about 1.0% to about 30%, about 1.0% to about 25%, about 1% to 20%, about 1% to about 10%, about 1% to about 5%, or about 1% to about 2%), by weight of a strong acid, preferably wherein the strong acid is 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, or p-toluenesulfonic acid, and more preferably 1,2-ethanedisulfonic acid, Form El may comprise: about 0% to about 40%, about 1% to about 35%, about 0.5% to about 35%, about 1% to about 30%, about 1% to about 25%, about 1% to about 20%, about 1% to about 10%, about 1% to about 5%, or about 1% to about 2% or about 0.1% to about 2%, or about 0.1% to about 1%), by weight of 1,2-ethanedisulfonic acid.
[00104] The above crystalline forms can be used to prepare other crystalline polymorphs of Firibastat, Firibastat salts or co-crystals and their solid state forms.
[00105] The present disclosure encompasses a process for preparing other solid state forms of Firibastat, Firibastat salts or co-crystals and solid state forms thereof. The process includes preparing any one or a mixture of the above disclosed form of Firibastat by the processes of the present disclosure, and converting it to said other form of Firibastat or Firibastat salt or co crystal.
[00106] The present disclosure includes a process for preparation of Form A of Firibastat wherein the process comprises crystallization of Firibastat in the presence of a strong acid, such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-
toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
[00107] In embodiments, the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of a strong acid, preferably a strong acid such as but not limited to: 1,2- ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
[00108] In one embodiment the reaction mixture in step (a) is performed a slurry. In embodiments step (a) is performed in a polar solvent which is capable of dissolving the acid, or in which the acid is miscible, preferably wherein the solvent is an alcohol (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol. The strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat. . The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C.
In embodiments, in step (c) the solvent is separated by centrifuge.
[00109] The present disclosure includes a process for preparation of Form A wherein the process comprises crystallization of Firibastat in the presence of 1,2-ethanedisulfonic acid in a solvent or a mixture of solvents wherein 1,2-ethanedisulfonic acid is dissolved, or in the presence of Benzathine in a solvent or a mixture of solvents wherein benzathine is dissolved. The strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to equivalents relative to Firibastat. The benzathine is preferably used in an amount of: about 0.2 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, or about 0.5 to about 1.5, or about 0.6 to about 1.4 equivalents relative to Firibastat.
[00110] In one embodiment, the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of 1,2-ethanedisulfonic acid, wherein 1,2-ethanedisulfonic acid is dissolved in the reaction mixture;
b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
[00111] In one embodiment the reaction mixture in step (a) is performed a slurry. In embodiments step (a) is performed in a polar solvent, which is capable of dissolving the 1,2- ethanedisulfonic acid preferably an alcohol (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (c) the solvent is separated by centrifuge. The 1,2-ethanedisulfonic acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat.
[00112] In another embodiment, the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of benzathine, wherein benzathine is dissolved in the reaction mixture b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; d) optionally washing and/or drying Form A.
[00113] In one embodiment the reaction mixture in step (a) is performed a slurry. In embodiments step (a) is performed in a polar solvent, which is capable of dissolving the benzathine preferably an alcohol (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol. . The benzathine is preferably used in an amount of: about 0.2 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, or about 0.5 to about 1.5, or about 0.6 to about 1.4 equivalents relative to Firibastat. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (c) the solvent is separated by centrifuge.
[00114] In another embodiment, the process for preparing Form A comprises: a) providing Firibastat, preferably in a hydrated form (preferably Form HI), in a solvent or mixture of solvents performed in a polar solvent, preferably alcohol (particularly a C1-C6 alcohol and more (particularly a C1-C3 alcohol), more preferably ethanol) in the presence of an inorganic or organic acid (preferably a mineral acid or a carboxylic acid or a sulfonic acid, and more preferably sulfuric acid or methane sulfonic acid, or para-toluene sulfonic acid);
b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
[00115] In one embodiment the reaction mixture in step (a) is performed a slurry. In embodiments step (a) is performed in a polar solvent, preferably alcohol, (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol) more preferably ethanol. The acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to equivalents relative to Firibastat. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (c) the solvent is separated by centrifuge.
[00116] According to any aspect or embodiment of the process described herein for preparing Form A of Firibastat, the starting material may be any (preferably hydrated) form of Firibastat, such as Form HI or H2, or any mono-, di, or tri-hydrate form, including the trihydrate form disclosed in WO 2012/045849. According to any aspect or embodiment of the process for preparing Form A of Firibastat, after isolating the product, the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
[00117] According to any aspect or embodiment of the process for preparing Form A of Firibastat, the solvent is a polar solvent, and particularly a polar protic solvent, wherein the polar solvent is an alcohol, more particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol), more preferably ethanol or isopropanol .
[00118] The present disclosure includes a process for preparation of Firibastat Form B wherein the process comprises: a) providing a slurry of Firibastat in a one or more solvents comprising an acid; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form B; and d) optionally washing and/or drying Form B.
[00119] In one embodiment, the sole solvent in step (a) is an acid, preferably an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 carboxylic acid, and more preferably acetic acid or propionic acid. Accordingly, the process for preparing Firibastat Form B comprise crystallising
Firibastat from a solvent which is a C1-C6 carboxylic acid, a C2-C5 carboxylic acid, and more preferably acetic acid or propionic acid. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 60 °C. In embodiments, in step (c) the solvent is separated by centrifuge.
[00120] According to any aspect or embodiment of the process for preparing Form B of Firibastat, after isolating the product, the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
[00121] The present disclosure includes a process for preparation of Firibastat Form El wherein the process comprises: a) contacting Firibastat with 1,2-ethanedisulfonic acid wherein the molar ratio of Firibastat and 1,2-ethanedisulfonic acid is about 1:1 in the presence of one or more solvents wherein 1,2- ethanedisulfonic acid is not dissolved; b) ) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Firibastat Form El; and d) optionally washing and/or drying Firibastat Form El.
[00122] In another aspect, the reaction mixture in step (a) is a slurry and preferably the Firibastat provided as starting material is a hydrated form or an anhydrous form. For example, the starting material in step (a) of the process for preparing Form El as described in any of the processes herein, may be any form of Firibastat, such as Form HI or H2, or any mono-, di, or tri hydrate form, including the trihydrate form disclosed in WO 2012/045849, or may be Form A as described herein. The 1,2-ethanedisulfonic acid may be used in an amount of: about 0.2 to about 2, about 0.5 to about 1.5, about 0.6 to about 1.2, about 0.8 to about 1.2, or about 0.9 to about 1.1, or about 1 mole equivalents relative to Firibastat.
[00123] According to any aspect or embodiment of the process for preparing Form El of Firibastat, after isolating the product, the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C or about 40°C to about 60°C.
[00124] I any aspect or embodiment of the process for preparing Form El, the 1,2- ethanesdisulfonic acid is used as a dihydrate.
[00125] In embodiments, the solvent in step (a) is a polar aprotic solvent, preferably ether solvents, more preferably THF, halogenated solvents, more preferably dichloromethane, or ester solvents, more preferably ethyl acetate.
[00126] In embodiments the solvents in step (a) comprises one or more aromatic solvents such as toluene. Particularly, the reaction mixture in step (a) comprises a mixture of an aromatic solvent and an ester solvent, preferably a mixture of toluene and ethyl acetate. Preferably the ratio of ethyl acetate to toluene is from about 1 :6 to about 2:1, preferably from about 1 :4 to about 1:1, more preferably about 1:2.
[00127] The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (c) the solvent is separated by centrifuge.
[00128] The present disclosure further provides a process for the preparation of Firibastat: piperazine, preferably Form PI, comprising:
(i) contacting Firibastat with piperazine wherein the molar ratio of Firibastat and piperazine is from about 1 :0.5 to about 1 :5 in the presence of one or more solvents;
(ii) optionally removing the solvents;
(iii) optionally isolating Firibastafpiperazine; and
(iv) optionally drying Firibastat: piperazine.
[00129] In one aspect the reaction mixture in step (i) is a solution. In embodiments step (i) comprises contacting Firibastat and piperazine in water or in a mixture of solvents comprising water and step (ii) comprises removing the solvent or solvent mixture.
[00130] In another aspect, the reaction mixture in step (i) is a slurry and preferably the Firibastat provided as starting material is a hydrated form. In embodiments, the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (ii) the solvent is separated by centrifuge.
[00131] According to any aspect or embodiment of the process for preparing Form PI of Firibastat, after isolating the product, the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 70°C, about 35°C to about 65°C, or about 40°C to about 60°C.
[00132] The present disclosure further provides a process for the preparation of a Firibastat: L-Proline, preferably Form P2, comprising:
(i) contacting Firibastat with L-Proline in the presence of one or more solvents;
(ii) optionally removing the solvents;
(iii) optionally isolating Firibastat: L-Proline; and
(iv) optionally drying Firibastat: L-Proline.
[00133] In one aspect the reaction mixture in step (i) is a solution. In embodiments step (i) comprises contacting Firibastat and L-Proline in one or more polar solvents and step (ii) comprises removing the solvent or solvent mixture.
[00134] In another aspect, the reaction mixture in step (i) is a slurry. In embodiments the Firibastat provided as starting material is a non-hydrated form. In embodiments, the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol. The reaction mixture may optionally be heated to a temperature of from about 30 °C to about 50 °C. In embodiments, in step (ii) the solvent is separated by centrifuge.
[00135] According to any aspect or embodiment of the process for preparing Form P2 of Firibastat, after isolating the product, the solid may be dried, preferably under reduced pressure, and particularly at a temperature of: about 25°C to about 90°C; about 30°C to about 80°C; about 35°C to about 85°C, about 35°C to about 80°C or about 40°C to about 75°C.
[00136] In embodiments, the molar ratio of Firibastat to L-Proline is from about 1 :4 to about 4:1, or from about 1:3 to about 3:1, or from about 1:2.5 to about 2.5:1. In embodiments the molar ratio of Firibastat to L-Proline is about 1 :2.
[00137] The present disclosure further relates to a product obtainable by any of the processes described herein.
[00138] Any of the above described processes may further comprise a step of combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
[00139] The present disclosure provides the above described crystalline polymorphs of Firibastat, Firibastat salts or co-crystals for use in the preparation of pharmaceutical compositions comprising Firibastat, Firibastat salts or co-crystals and/or crystalline polymorphs thereof.
[00140] The present disclosure also encompasses the use of crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure for the preparation of
pharmaceutical compositions of crystalline polymorph Firibastat, Firibastat salts or co-crystals and/or crystalline polymorphs thereof.
[00141] The present disclosure includes processes for preparing the above mentioned pharmaceutical compositions. The processes include combining any one or a combination of the crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure with at least one pharmaceutically acceptable excipient.
[00142] Pharmaceutical combinations or formulations of the present disclosure contain any one or a combination of the solid state forms of Firibastat, Firibastat salts or co-crystals of the present disclosure. In addition to the active ingredient, the pharmaceutical formulations of the present disclosure can contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
[00143] Diluents increase the bulk of a solid pharmaceutical composition, and can make a pharmaceutical dosage form containing the composition easier for the patient and caregiver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g., Avicel®), microfme cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g., Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol, and talc.
[00144] Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet, can include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate, and starch. [00145] The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach can be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g., Ac- Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g.,
Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g., Explotab®), and starch.
[00146] Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing. Excipients that can function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, and tribasic calcium phosphate.
[00147] When a dosage form such as a tablet is made by the compaction of a powdered composition, the composition is subjected to pressure from a punch and dye. Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc stearate. [00148] Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that can be included in the composition of the present disclosure include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.
[00149] Solid and liquid compositions can also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
[00150] In liquid pharmaceutical compositions of the present invention, Firibastat, Firibastat salts or co-crystals and any other solid excipients can be dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol, or glycerin. [00151] Liquid pharmaceutical compositions can contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that can be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, and cetyl alcohol.
[00152] Liquid pharmaceutical compositions of the present invention can also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, xanthan gum and combinations thereof.
[00153] Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol, and invert sugar can be added to improve the taste.
[00154] Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxyl toluene, butylated hydroxyanisole, and ethylenediamine tetraacetic acid can be added at levels safe for ingestion to improve storage stability.
[00155] According to the present disclosure, a liquid composition can also contain a buffer such as gluconic acid, lactic acid, citric acid, or acetic acid, sodium gluconate, sodium lactate, sodium citrate, or sodium acetate. Selection of excipients and the amounts used can be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
[00156] The solid compositions of the present disclosure include powders, granulates, aggregates, and compacted compositions. The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant, and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, in embodiments the route of administration is oral. The dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
[00157] Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches, and lozenges, as well as liquid syrups, suspensions, and elixirs. [00158] The dosage form of the present disclosure can be a capsule containing the composition, such as a powdered or granulated solid composition of the disclosure, within either a hard or soft shell. The shell can be made from gelatin and optionally contain a plasticizer such as glycerin and/or sorbitol, an opacifying agent and/or colorant.
[00159] The active ingredient and excipients can be formulated into compositions and dosage forms according to methods known in the art.
[00160] A composition for tableting or capsule filling can be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried, and then screened and/or milled to the desired particle size. The granulate can then be tableted, or other excipients can be added prior to tableting, such as a glidant and/or a lubricant.
[00161] A tableting composition can be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients can be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules can subsequently be compressed into a tablet.
[00162] As an alternative to dry granulation, a blended composition can be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate, and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
[00163] A capsule filling of the present disclosure can include any of the aforementioned blends and granulates that were described with reference to tableting, but they are not subjected to a final tableting step.
[00164] A pharmaceutical formulation of Firibastat, Firibastat salts or co-crystals can be administered. Firibastat, Firibastat salts or co-crystals may be formulated for administration to a mammal, in embodiments to a human, by injection. Firibastat, Firibastat salts or co-crystals can be formulated, for example, as a viscous liquid solution or suspension, such as a clear solution, for injection. The formulation can contain one or more solvents. A suitable solvent can be selected by considering the solvent's physical and chemical stability at various pH levels, viscosity (which would allow for syringeability), fluidity, boiling point, miscibility, and purity. Suitable solvents include alcohol USP, benzyl alcohol NF, benzyl benzoate USP, and Castor oil USP. Additional substances can be added to the formulation such as buffers, solubilizers, and
antioxidants, among others. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed.
[00165] The crystalline polymorphs of Firibastat, Firibastat salts or co-crystals and the pharmaceutical compositions and/or formulations of Firibastat, Firibastat salts or co-crystals of the present disclosure can be used as medicaments, in embodiments in the treatment of hypertension.
[00166] The present disclosure also provides methods of treating hypertension by administering a therapeutically effective amount of any one or a combination of the crystalline polymorphs of Firibastat, Firibastat salts or co-crystals of the present disclosure, or at least one of the above pharmaceutical compositions and/or formulations, to a subject in need of the treatment.
[00167] Having thus described the disclosure with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the disclosure as described and illustrated that do not depart from the spirit and scope of the disclosure as disclosed in the specification. The Examples are set forth to aid in understanding the disclosure but are not intended to, and should not be construed to limit its scope in any way. [00168] Further aspects and embodiments of the present disclosure are set out in the numbered clauses below:
Al. A crystalline form, designated Form A, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ± 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 3; c. a solid state 13C NMR spectrum having characteristic peaks at 49.9, 49.0, 46.3, 42.9, 39.5, 31.0 and 26.9 ppm ± 0.2 ppm; d. a solid state 13C NMR spectrum substantially as depicted in Figure 8 or in Figure 8A; and e. combination of these data.
A2. A crystalline product according to Clause Al, designated Form A, characterized by the XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ± 0.2 degrees 2-
theta, and also having one, two, three or four additional peaks selected from 18.8, 21.7, 22.3,
26.6 and 27.2 degrees two theta ± 0.2 degrees two theta.
A3. A crystalline form, designated Form A, according to any one of Clauses A1 or A2 wherein the form is anhydrous.
A4. A crystalline product according to any one of Clauses A1-A3 designated Form A which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
A5. A crystalline product according to any one of Clauses A1-A3, or A4, designated Form A, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat.
A6. A process for preparation of Form A, according to any one of clauses A1-A5, wherein the process comprises crystallization of Firibastat in the presence of 1,2-ethanedisulfonic acid in a solvent or a mixture of solvents wherein 1,2-ethanedisulfonic acid is dissolved, or in the presence of Benzathine in a solvent or a mixture of solvents wherein benzathine is dissolved.
A7. A process according to clause A6 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of 1,2-ethanedisulfonic acid, wherein 1,2-ethanedisulfonic acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
A8. A process for preparation of Form A, according to any one of clauses A1-A5, wherein the process comprises crystallization of Firibastat in the presence of a strong acid, such as, but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid in a solvent or a mixture of solvents wherein the acid is dissolved in the solvent or the mixture of solvents.
A9. A process according to clause A8 wherein the process comprises: a) providing Firibastat, in a solvent or mixture of solvents in the presence of a strong
acid, preferably a strong acid such as but not limited to: 1,2-ethanedisulfonic acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, wherein the acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
A10. A process according to clause A8 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form in a solvent or mixture of solvents performed in the presence of an inorganic or organic acid (preferably a mineral acid or a carboxylic acid or a sulfonic acid, and more preferably sulfuric acid or methane sulfonic acid or para-toluene sulfonic acid, wherein the acid is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
A11. A process according to Clause A7, A9 or A10 wherein the reaction mixture is step (a) is a slurry.
A12. A process according to any one of Clauses A7-A11 wherein step (a) is performed in a polar solvent which is capable of dissolving the acid, or in which the acid is miscible, preferably alcohol, particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol, more preferably ethanol.
A13. A process according to any one of clauses A7-A12 wherein the strong acid is preferably used in an amount of: about 0.1 to about 4, about 0.2 to about 3.5, about 0.2 to about 3, or about 0.3 to about 3, or about 0.3 to about 2.7 equivalents relative to Firibastat
A14. A process according to any one of Clauses A7-A13 wherein the reaction mixture is heated to temperature of from about 30 °C to about 50 °C.
A15. A process according to any one of Clauses A7-A14 wherein in step (c) the solvent is separated by centrifuge.
A16. A process according to clause A6 wherein the process comprises: a) providing Firibastat, preferably in a hydrated form, in a solvent or mixture of solvents in the presence of benzathine, wherein benzathine is dissolved in the reaction mixture; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form A; and d) optionally washing and/or drying Form A.
A17. A process according to Clause A16 wherein the reaction mixture is step (a) is a slurry.
A18. A process according to any one of Clauses A16-A17 wherein step (a) is performed in a polar solvent, which is capable of dissolving benzathine, or in which benzathine is miscible, preferably alcohol, (particularly a C1-C6 alcohol and more particularly a C1-C3 alcohol)more preferably ethanol.
A19. A process according to any one of clauses A16-A18 wherein benzathine is preferably used in an amount of: about 0.2 to about 3, about 0.4 to about 2.5, about 0.4 to about 2, or about 0.5 to about 1.5, or about 0.6 to about 1.4 equivalents relative to Firibastat
A20. A process according to any one of Clauses A16-A19 wherein the reaction mixture is heated to temperature of from about 30 °C to about 50 °C.
A21. A process according to any one of Clauses A16-A20 wherein in step (c) the solvent is separated by centrifuge.
A22. A process according to any one of Clauses A6-A21 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
A23. A crystalline product obtainable by a process according to any one of Claims A6-A20.
A24. A pharmaceutical composition comprising a crystalline product according to any of Clauses A1-A5 or A23, and at least one pharmaceutically acceptable excipient.
A25. Use of a crystalline product according to any of Clauses A1-A5 or A23 for the preparation of a pharmaceutical composition and/or formulation.
A26. A process for preparing the pharmaceutical composition according to Clause A24, comprising combining a crystalline product according to any of Clauses A1-A5 or A23 with at least one pharmaceutically acceptable excipient.
A27. A crystalline product according to any of Clauses A1-A5 or A23, or a pharmaceutical composition according to Clause A24, for use as a medicament.
A28. A crystalline product according to any of Clauses A1-A5 or A23, or a pharmaceutical composition according to Clause A19, for use in the treatment of hypertension
A29. A method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses A1-A5 or A23, or a pharmaceutical composition according to Clause A24, to a subject in need of the treatment.
A30. Use of a crystalline product according to any of Clauses A1-A5 or A23, in the preparation of another solid state form of Firibastat or Firibastat salt
A31. A process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Al- A5 or A23, and converting it to another a solid state form thereof or Firibastat salt.
Bl. A crystalline form, designated Form B, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ± 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 4; and c. combination of these data.
B2. A crystalline product according to Clause Bl, designated Form B, characterized by the XRPD pattern having peaks at 9.4, 13.3, 18.5, 20.1 and 23.3 degrees 2-theta ± 0.2 degrees 2- theta, and also having one, two, three or four additional peaks selected from 17.6, 17.9, 22.3,
24. land 25.5 degrees two theta ± 0.2 degrees two theta.
B3. A crystalline product according to any one of Clauses B1-B2 designated Form B which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
B4. A crystalline product according to any one of Clauses B1-B2, or B3, designated Form B, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat.
B5. A process for preparation of Form B according to any one of clauses B1-B4 wherein the process comprises: a) providing a slurry of Firibastat in a one or more solvents comprising an acid; b) optionally heating the reaction mixture; c) optionally cooling and optionally isolating Form B; and d) optionally washing and/or drying Form B.
B6. A process according to Clause B5 wherein the sole solvent in step (a) is an acid, preferably an organic acid, particularly a C1-C6 carboxylic acid, a C2-C5 acid, and more preferably acetic acid or propionic acid.
B7. A process according to any one of clauses B5-B6 wherein the reaction mixture is heated to a temperature of from about 30 °C to about 60 °C.
B8. A process according to any one of clauses B5-B7 wherein in step (c) the solvent is separated by centrifuge.
B9. A process according to any one of Clauses B5-B8 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
B10. A crystalline product obtainable by a process according to any one of Claims B5-B8.
B11. A pharmaceutical composition comprising a crystalline product according to any of Clauses B1-B4 or B10, and at least one pharmaceutically acceptable excipient.
B12. Use of a crystalline product according to any of Clauses B1-B4 or B10 for the preparation of a pharmaceutical composition and/or formulation.
B13. A process for preparing the pharmaceutical composition according to Clause B11, comprising combining a crystalline product according to any of Clauses B1-B4 or B10 with at least one pharmaceutically acceptable excipient.
B14. A crystalline product according to any of Clauses B1-B4 or BIO, or a pharmaceutical composition according to Clause B 12, for use as a medicament.
B15. A crystalline product according to any of Claims B1-B4 or BIO, or a pharmaceutical composition according to Claim B11, for use in the treatment of hypertension.
B16. A method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses B1-B4 or BIO, or a pharmaceutical composition according to Clause B11, to a subject in need of the treatment.
B17. Use of a crystalline product according to any of Clauses B1-B4 or BIO, in the preparation of another solid state form of Firibastat or Firibastat salt.
B18. A process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Bl- B4 or BIO, and converting it to another a solid state form thereof or Firibastat salt.
Cl. Crystalline Firibastat: piperazine.
C2. Crystalline Firibastat: piperazine which is a co-crystal.
C3. Crystalline Firibastat: piperazinium which is a salt (i.e. Firibastat piperazine salt), optionally wherein the ratio of Firibastat to piperazine is about 1: 1.5 to about 1.5: 1, preferably between about 1: 1.25 and about 1.25: 1, about 1:2 or about 1:1, and preferably about 1:2.
C4. A crystalline product according to any one of Clauses C1-C3, designated Form PI, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ±
0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 6; and c. combinations of these data.
C5. A crystalline product according to any one of Clauses C1-C4, designated Form PI, characterized by the XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2- theta ± 0.2 degrees 2-theta, and also having one, two, three or four additional peaks selected from 15.7, 20.0, 20.7, 25.1 and 27.7 degrees two theta ± 0.2 degrees two theta.
C6. A crystalline product according to any one of Clauses C1-C5, designated Form PI which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat: piperazine.
C7. A crystalline product according to any one of Clauses C1-C5, or C6, designated Form PI, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat: piperazine.
C8. A process for the preparation of a crystalline product according to any one of Clauses C1-C7 comprising:
(i) contacting Firibastat or a salt thereof with piperazine wherein the molar ratio of Firibastat and piperazine is from about 1 :0.5 to about 1 :5 in the presence of one or more solvents;
(ii) optionally removing the solvents;
(iii) optionally isolating Firibastat: piperazine; and
(iv) optionally drying Firibastat: piperazine.
C9. A process according to clause C8 wherein the reaction mixture in step (i) is a solution.
CIO. A process according to Clause C8 or clause C9 wherein step (i) comprises contacting Firibastat and piperazine in water or in a mixture of solvents comprising water and step (ii) comprises removing the solvent or solvent mixture.
Cl 1. A process according to Clause C8 wherein the reaction mixture in step (i) is a slurry.
C12. A process according to Clauses C8 or Cl 1, wherein the Firibastat provided as starting material is in a hydrated form.
C13. A process according to any of Clauses C8, Cl 1 or C12, wherein the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol.
C14. A process according to any one of clauses C8, Cl 1, C12 or C13 wherein the reaction mixture is optionally heated to a temperature of about 30 °C to about 50 °C.
C15. A process according to any one of clauses C8, Cl 1, C12, C13 or C14 wherein in step (ii)
the solvent is separated by centrifuge.
Cl 6. A process according to any one of Clauses C8-C15 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
Cl 7. A crystalline product obtainable by a process according to any one of Claims C8-C15.
C18. A pharmaceutical composition comprising a crystalline product according to any of Clauses C1-C7 or Cl 7, and at least one pharmaceutically acceptable excipient.
C19. Use of a crystalline product according to any of Clauses C1-C7 or C17 for the preparation of a pharmaceutical composition and/or formulation.
C20. A process for preparing the pharmaceutical composition according to Clause Cl 8, comprising combining a crystalline product according to any of Clauses C1-C7 or C17 with at least one pharmaceutically acceptable excipient.
C21. A crystalline product according to any of Clauses C1-C7 or Cl 7, or a pharmaceutical composition according to Clause Cl 8, for use as a medicament.
C22. A crystalline product according to any of Claims C1-C7 or Cl 7, or a pharmaceutical composition according to Claim Cl 8, for use in the treatment of hypertension
C23. A method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses C1-C7 or Cl 7, or a pharmaceutical composition according to Clause Cl 8, to a subject in need of the treatment.
C24. Use of a crystalline product according to any of Clauses C1-C7 or Cl 7, in the preparation of another solid state form of Firibastat: piperazine or Firibastat salt.
C25. A process for preparing a solid state form of Firibastat: piperazine or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses C1-C7 or Cl 7, and converting it to another a solid state form thereof or Firibastat salt.
Dl. A crystalline Firibastat designated Form El, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-
theta ± 0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 5; c. a solid state 13C NMR spectrum having characteristic peaks at 29.4, 37.9, 44.9, 47.0, and 50.3 ppm ± 0.2 ppm; d. a solid state 13C NMR spectrum substantially as depicted in Figure 9 or in Figure 9A; and e. combinations of these data.
D2. A crystalline product according to Clause Dl, designated Form El, characterized by the XRPD pattern having peaks at 11.8, 18.1, 20.6, 21.3 and 24.6 degrees 2-theta ± 0.2 degrees 2- theta, and also having one, two, three or four additional peaks selected from 22.3, 22.9, 23.3, 23.7 and 27.3 degrees two theta ± 0.2 degrees two theta.
D3. A crystalline form, designated Form El, according to any one of Clauses Dl or D2 wherein the form is a hydrate.
D4. A crystalline product according to any of Clauses D1-D3, designated Form El which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat
D5. A crystalline product according to any of Clauses D1-D3 or D4, designated Form El, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat
D6. A process for the preparation of a crystalline product according to any of Clauses D1-D5, comprising:
(a) contacting Firibastat with 1,2-ethanedisulfonic acid wherein the molar ratio of Firibastat and 1,2-ethanedisulfonic acid is about 1:1 in the presence of one or more solvents wherein 1,2-ethanedisulfonic acid is not dissolved;
(b) optionally heating the reaction mixture;
(c) optionally cooling and optionally isolating Firibastat Form El; and
(d) optionally washing and/or drying Firibastat Form El .
D7. A process according to clause D6 wherein the reaction mixture in step (a) is a slurry.
D8. A process according to any one of Clause D6 or clause D7 wherein the Firibastat provided as starting material is in a hydrated form.
D9. A process according to any one of Clauses D6-D8 wherein the solvent comprises one or more polar aprotic solvents, preferably ether solvents, more preferably THF, halogenated solvents, more preferably dichloromethane or ester solvents, more preferably ethyl acetate.
DIO. A process according to any one of Clauses D6-D8 wherein the solvent comprises one or more aromatic solvents, preferably toluene.
D11. A process according to any one of Clauses D6-D10 wherein the reaction mixture is optionally heated to a temperature of about 30 °C to about 50 °C.
D12. A process according to any one of Clauses D6-D11 wherein in step (c) the solvent is separated by centrifuge.
D13. A process according to any of Clauses D6-D12 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
D14. A crystalline product obtainable by a process according to any of Clauses D6-D12.
D15. A pharmaceutical composition comprising a crystalline product according to any of Clauses D1-D5 or D14, and at least one pharmaceutically acceptable excipient.
D16. Use of a crystalline product according to any of Clauses D1-D5 or D14 for the preparation of a pharmaceutical composition and/or formulation.
D17. A process for preparing the pharmaceutical composition according to Clause D15, comprising combining a crystalline product according to any of Clauses D1-D5 or D14 with at least one pharmaceutically acceptable excipient.
D18. A crystalline product according to any of Clauses D1-D5 or D 14, or a pharmaceutical composition according to Clause D17, for use as a medicament.
D19. A crystalline product according to any of Claims D1-D5 or D14, or a pharmaceutical composition according to Clause D 15, for use in the treatment of hypertension
D20. A method of treating hypertension comprising administering a therapeutically effective
amount of a crystalline product according to any of Clauses D1-D5 or D 14, or a pharmaceutical composition according to Clause D 15, to a subject in need of the treatment.
D21. Use of a crystalline product according to any of Clauses D1-D5 or D14, in the preparation of another solid state form of Firibastat or Firibastat salt.
D22. A process for preparing a solid state form of Firibastat or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses Dl- D5 or D14, and converting it to another a solid state form thereof or Firibastat salt.
El. Crystalline Firibastat: L-Proline.
E2. Crystalline Firibastat: L-Proline which is a co-crystal.
E3. Crystalline Firibastat: L-Proline which is a salt.
E4. A crystalline product according to any one of Clauses E1-E3, designated Form P2, which is characterized by data selected from one or more of the following:
(i) an XRPD pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2-theta ± 0.2 degrees 2-theta;
(ii) an XRPD pattern as depicted in Figure 7; and
(iii) combinations of these data.
E5. A crystalline product according to any one of Clauses E1-E4, designated Form P2, characterized by the XRPD pattern having peaks at 12.9, 17.8, 20.2, 23.5 and 25.7 degrees 2- theta ± 0.2 degrees 2-theta, and also having one, two, three or four additional peaks selected from 18.5, 19.0, 19.7, 21.3 and 21.9 degrees two theta ± 0.2 degrees two theta.
E6. A crystalline product according to any one of Clauses E1-E5, designated Form P2 which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
E7. A crystalline product according to any one of Clauses E1-E5 , or E6, designated Form P2, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat.
E8. A process for the preparation of a crystalline product according to any one of Clauses E1-E7
comprising:
(i) contacting Firibastat or a salt thereof with L-Proline in the presence of one or more solvents;
(ii) optionally removing the solvents;
(iii) optionally isolating Firibastat: L-Proline; and
(iv) optionally drying Firibastat: L-Proline.
E9. A process according to clause E8 wherein the reaction mixture in step (i) is a solution.
E10. A process according to Clause E8 or clause E9 wherein step (i) comprises contacting Firibastat and L-Proline in one or more Polar solvents and step (ii) comprises removing the solvent or solvent mixture.
El 1. A process according to Clauses E8 or E10 wherein the reaction mixture in step (i) is a slurry.
E12. A process according to Clauses E8 or Ell, wherein the Firibastat provided as starting material is in a non-hydrated form.
E13. A process according to any of Clauses E8, El 1 or E12, wherein the solvent is a polar solvent, preferably an alcohol, more preferably isopropanol.
E14. A process according to any one of clauses E8, Ell, E12 or E13 wherein the reaction mixture is optionally heated to a temperature of about 30 °C to about 50 °C.
E15. A process according to any one of clauses E8, Ell, E12, E13 or E14 wherein in step (ii) the solvent is separated by centrifuge.
El 6. A process according to any one of clauses E8-E15 wherein the molar ration of Firibastat to L-Proline is from about 1:4 to about 4:1, preferably from about 1:3 to about 3:1, more preferably the ratio is about 1:2.
E17. A process according to any one of Clauses E8-E16 further comprising combining the crystalline product with at least one pharmaceutically acceptable excipient to provide a pharmaceutical composition.
E18. A crystalline product obtainable by a process according to any one of Claims E8-E16.
E19. A pharmaceutical composition comprising a crystalline product according to any of Clauses E1-E7 or E18, and at least one pharmaceutically acceptable excipient.
E20. Else of a crystalline product according to any of Clauses E1-E7 or E18 for the preparation of a pharmaceutical composition and/or formulation.
E21. A process for preparing the pharmaceutical composition according to Clause El 9, comprising combining a crystalline product according to any of Clauses E1-E7 or E18 with at least one pharmaceutically acceptable excipient.
E22. A crystalline product according to any of Clauses E1-E7 or E18, or a pharmaceutical composition according to Clause El 9, for use as a medicament.
E23. A crystalline product according to any of Clauses E1-E7 or Cl 8, or a pharmaceutical composition according to Clause E19, for use in the treatment of hypertension.
E24. A method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Clauses E1-E7 or El 8, or a pharmaceutical composition according to Clause El 9, to a subject in need of the treatment.
E25. Else of a crystalline product according to any of Clauses E1-E7 or E18, in the preparation of another solid state form of Firibastat: L-Proline or Firibastat salt.
E26. A process for preparing a solid state form of Firibastat: L-Proline or Firibastat salt comprising preparing any one or a combination of a crystalline product according to any one of Clauses E1-E7 or E18, and converting it to another a solid state form thereof or Firibastat salt.
Powder X-ray Diffraction C'XRPD") method
[00169] XRPD analysis was performed on Bruker powder X-Ray diffractometer model D8 ADVANCE equipped with a solid state detector. Copper radiation of 1.54060 A was used. Scanning parameters: range: 2-40 degrees two-theta; scan mode; step size: 0.05°.
The positions of the peaks were corrected respective to the position of the silicon theoretical peak at 28.45 degrees two theta.
Solid-state NMR
[00170] Solid-state NMR spectra were measured at 11.7 T using a Bruker Avance III HD 500 US/WB NMR spectrometer (Karlsruhe, Germany, 2013). The 13C CPMAS NMR spectra employing cross-polarization were acquired using the standard pulse scheme at spinning frequency of 18 kHz. The recycle delay was 8 s and the cross-polarization contact time was 2 ms. The strength of spin-locking fields B1(13C) expressed in frequency units w1/2p=gB1 was 64 kHz.
EXAMPLES
Preparation of starting materials
[00171] Firibastat can be prepared according to methods known from the literature, for example as described in International Publication No. WO 2004/007441.
Example 1: Preparation of crystalline Firibastat
[00172] Water (10 ml, 10V) was added to Firibastat (lgram, 2.7 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 10 minutes to obtain complete dissolution followed by filtration using filter disk. Next, Isopropyl alcohol as anti solvent (13 ml) was added drop-wise to the stirred clear solution at 40°C. The solution was cooled to room temperature and then stirred at room temperature during 18 hours. The obtained precipitation was then separated by centrifuge to afford a white wet solid and dried in a vacuum oven at 45°C over a period of 16 hours to afford a white solid. Next, the dry solid was exposed to 100% relative humidity (RH) at room temperature for 6 days to afford a white solid.
Example 2: Preparation of Firibastat Form HI Procedure A
[00173] Mixture of Diehl orom ethane and Acetonitrile (1:1, 60 ml, 200V) was added to
Firibastat (300 mg, 0.81 mmol, prepared according to example 1), to obtain a slurry. The slurry was stirred at 60°C over a period of 48 hours. Then was cooled to room temperature and was separated by centrifuge. Then, the solid was dried in a vacuum oven at 60 °C over a period of 16 hours to afford white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form HI and the XRPD pattern is presented in Figure 1.
Procedure B
[00174] Dioxane (60 ml, 200V) was added to Firibastat (40 mg, 0.1 mmol, prepared according to example 1) to obtain a slurry. The slurry was stirred at 60°C over a period of 48 hours. The obtained slurry was cooled to room temperature and then was separated by centrifuge. The wet solid was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form HI.
Example 3: Preparation of Firibastat Form H2 Procedure A
[00175] Water (0.5 ml, 10V) was added to Firibastat (50 mg, 0.13 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 10 minutes to obtain complete dissolution followed by filtration using filter disk. Next, Acetone as anti-solvent (0.5 ml) was added drop-wise to the stirred clear solution at 40°C. The solution was cooled to room temperature and then stirred at room temperature during 18 hours. The obtained precipitate was then separated by centrifuge to afford a white wet solid and dried in a vacuum oven at 45°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form H2 and the XRPD pattern is presented in Figure 2.
Example 4: Preparation of Firibastat Form A Procedure A
[00176] Ethanol (6 ml, 20V) was added to Firibastat (300 mg, 0.81 mmol, prepared according to example 3, procedure A, and 1,2-Ethanedisulfonic acid dihydrate (72 mg, 0.3 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 72 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml). The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A and the XRPD pattern is presented in Figure 3.
Procedure B
[00177] Ethanol (3 ml, 10V) was added to Firibastat (300 mg, 0.81 mmol, prepared according to example 3, procedure A) and Benzathine (0.2 ml, 0.83 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 24 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml). The white wet solid was dried in a vacuum oven at 60°C over a
period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
Procedure C
[00178] Ethanol (1 ml, 10V) was added to Firibastat (100 mg, 0.21 mmol, prepared according to example 3, procedure A) and Benzathine (0.03 ml, 0.13 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 72 hours, then was cooled to room temperature and was separated by centrifuge followed by washing with Ethanol (3*1 ml). The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
Procedure D
[00179] Ethanol (1 ml, 10V) was added to Firibastat (100 mg, 0.21 mmol, prepared according to example 1) and Benzathine (0.07 ml, 0.26 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 24 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 40°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
Procedure E
[00180] Isopropyl alcohol (0.5 ml, 10V) was added to Firibastat (50 mg, 0.12 mmol, prepared according to example 3, procedure A) and Benzathine (0.07 ml, 0.26 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form A.
Procedure F
[00181] Ethanol (50 ml, 20V) was added to Firibastat (2.5 grams, 6.8 mmol), prepared according to example 2, procedure B, and 1,2-Ethanedisulfonic acid dihydrate (600 mg, 2.5 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and stirred for 120 hours. Then, the solid was separated by Buchner followed by washing with Ethanol (3*7.5
ml). The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A.
Procedure G
[00182] Ethanol (1 ml, 20V) was added to Firibastat (57 mg, 0.15 mmol), prepared according to example 2, procedure B, and 98% FbSCri (29 mΐ) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 48 hours. Then, the solid was separated by centrifuge. The wet solid was characterized by X-ray powder diffraction as Firibastat crystal Form A.
Procedure H
[00183] Ethanol (11.4 ml, 20V) was added to Firibastat (570 mg, 1.5 mmol), prepared according to example 2, procedure B, and 98% FbSCE (298 mΐ) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 72 hours. Then, the solid was separated by centrifuge. The wet solid was suspended in Ethanol (11.4 ml, 20V) to obtain slurry and 98% H2SO4 (298 mΐ) was added. The slurry was magnetically stirred and heated to 40°C over a period of 48 hours. Then, the solid was separated by centrifuge and dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form A.
Procedure
[00184] Ethanol (1 ml, 20V) was added to Firibastat (57 mg, 0.15 mmol), prepared according to example 2, procedure B, and Methansulfonic acid (17.6 mΐ) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 16 hours. Then, the solid was separated by centrifuge. The wet solid was characterized by X-ray powder diffraction as Firibastat crystal Form A.
Procedure J
[00185] Ethanol (1 ml, 20V) was added to Firibastat (57 mg, 0.15 mmol), prepared according to example 2, procedure B, and P-Toluenesulfonic acid monohydrate (27 mg) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C over a period of 16 hours. Then, the solid was separated by centrifuge. The wet solid was characterized by X-ray powder diffraction as Firibastat crystal Form A.
Example 5: Preparation of Firibastat Form B
Procedure A
[00186] Acetic acid (4 ml, 20V) was added to Firibastat (200 mg, 0.54 mmol, prepared according to example 3, procedure A) to obtain a slurry. The slurry was magnetically stirred and heated to 60°C. The slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form B and the XRPD pattern is presented in Figure 4.
Procedure B
[00187] Acetic acid (1 ml, 20V) was added to Firibastat (50 mg, 0.13 mmol, prepared according to example 1) to obtain a slurry. The slurry was magnetically stirred and heated to 60°C. The slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form B.
Procedure C
[00188] Propionic acid (1 ml, 20V) was added to Firibastat (50 mg, 0.13 mmol prepared according to example 3, procedure A) to obtain a slurry. The slurry was magnetically stirred and heated to 60°C. The slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 45°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form B.
Procedure D
[00189] Acetic acid (16.2 ml, 20V) was added to Firibastat (812 mg, 2.2 mmol, prepared according to example 2, procedure B) to obtain a slurry. The slurry was magnetically stirred and heated to 60°C. The slurry was stirred at 60°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid was dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form B.
Example 6: Preparation of Firibastat Crystal Form El
Procedure A
[00190] Toluene (11 ml, 20V) was added to Firibastat (536.5 mg, 1.35 mmol, prepared according to example 3, procedure A) and 1,2-Ethanedisulfonic acid dihydrate (298 mg, 1.35 mmol, 1:1 eq) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid and dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form El and the XRPD pattern is presented in Figure 5.
Procedure B
[00191] Tetrahydrofuran (6 ml, 20V) was added to Firibastat (50 mg, 0.12 mmol, prepared according to example 3, procedure A) and 1,2-Ethanedisulfonic acid dihydrate (24 mg, 0.11 mmol) to obtain a slurry. The slurry was magnetically stirred at room temperature over a period of 48 hours and then was separated by centrifuge. The wet solid was dried in a vacuum oven at 45°C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat crystal Form El.
Procedure C
[00192] Ethyl acetate (11 ml, 20V) was added to Firibastat (536.5 mg, 1.35 mmol, prepared according to example 3, procedure A) and 1,2-Ethanedisulfonic acid dihydrate (298 mg, 1.35 mmol, 1:1 eq) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid and dried in a vacuum oven at 60°C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form El.
Procedure D
[00193] Mixture of Ethyl acetate: Toluene (1 :2, 10 ml, 20V) was added to Firibastat Form A (500 mg, 1.35 mmol, example 4, procedure F) and 1,2-Ethanedisulfonic acid dihydrate (278 mg, 1.26 mmol) to obtain a slurry. The slurry was magnetically stirred and heated to 40°C. The slurry was stirred at 40°C over a period of 48 hours, then was cooled to room temperature and was separated by centrifuge. The wet solid and dried in a vacuum oven at 60°C over a period of
72 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat crystal Form El.
Example 7: Preparation of Firibastat: piperazine Form PI Procedure A
[00194] Water (2.3 ml, 46V) was added to Firibastat (50 mg, 0.13 mmol) to obtain a slurry. The slurry was stirred at room temperature to obtain clear solution. Then, a clear solution of piperazine in water (23.4 mg, 0.27 mmol in 0.16 ml) was added to the clear solution of Firibastat. The obtained clear mother-liquor was evaporated upon 70°C/300-35 mbar to give a precipitate. The obtained wet solid was dried in a vacuum oven at 60 °C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat: Piperazine crystal Form PI and the XRPD pattern is presented in Figure 6.
Procedure B
[00195] Isopropyl alcohol (0.93 ml, 10V) was added to piperazine (93.6 mg, 1.08 mmol) to obtain clear solution. Then, Firibastat prepared according to example 1, (200 mg, 0.54 mmol) was added to the clear solution of piperazine in IPA to obtain slurry. Additional portion of 1.064 ml of isopropyl alcohol was added to the stirred slurry. The slurry was then heated to 40°C and stirred at 40°C for 16 hours. The obtained wet solid was separated by centrifuge and washed twice with 1 ml IPA. The obtained solid was dried in a vacuum oven at 60 °C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat: Piperazine crystal Form PI.
Procedure C
[00196] Isopropyl alcohol (4.67 ml, 10V) was added to piperazine (467.5 mg, 5.4 mmol) to obtain clear solution. Then, Firibastat (1000 mg, 2.7 mmol, prepared according to example 2, procedure B) was added to the clear solution of piperazine in IPA to obtain slurry. Additional portion of 5.32 ml of isopropyl alcohol was added to the stirred slurry. The slurry was then heated to 40°C and stirred at 40°C for 16 hours. The obtained wet solid was separated by centrifuge and washed twice with 2 ml IPA. The obtained solid was dried in a vacuum oven at 60 °C over a period of 16 hours to afford a white solid, which was analyzed by X-ray powder diffraction and identified as Firibastat: Piperazine crystal Form PI.
Example 8: Preparation of Firibastat: L-Proline Form P2 Procedure A
[00197] Isopropyl alcohol (8 ml, 20V) was added to Firibastat Form A (that can be prepared according to example 4, procedure A) (400 mg, 1.08 mmol) to obtain a slurry. Then, L-Proline (250 mg) was added to the slurry. The slurry was then heated to 40°C and stirred at 40°C for 48 hours. The obtained wet solid was separated by centrifuge and was dried in a vacuum oven at 45 °C over a period of 16 hours to afford a white solid, which was characterized by X-ray powder diffraction as Firibastat: L-Proline crystal Form P2 and the XRPD pattern is presented in Figure 7.
Procedure B
[00198] Water (2.3 ml, 46V) was added to Firibastat (50 mg, 0.13 mmol) to obtain a slurry. The slurry was stirred at room temperature to obtain a clear solution. Then, a clear solution of L- Proline in water (31.2 mg in 0.1 ml) was added to the clear solution of Firibastat. The obtained clear mother-liquor was evaporated upon 70°C/300-35 mbar to give a precipitate. The obtained white solid was analyzed by X-ray powder diffraction and identified as Firibastat: L-Proline crystal Form P2.
Claims
1. A crystalline form of Firibastat, designated Form A, which is characterized by data selected from one or more of the following: a. an XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ±
0.2 degrees 2-theta; b. an XRPD pattern as depicted in Figure 3; c. a solid state 13C NMR spectrum having characteristic peaks at 49.9, 49.0, 46.3, 42.9, 39.5, 31.0 and 26.9 ppm ± 0.2 ppm; d. a solid state 13C NMR spectrum substantially as depicted in Figure 8 or in Figure 8A; and e. combinations of these data.
2. A crystalline product according to Claim 1, which is characterized by an XRPD pattern having peaks at 11.2, 16.3, 17.8, 19.9 and 23.4 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three or four additional peaks selected from 18.8, 21.7, 22.3, 26.6 and 27.2 degrees two theta ± 0.2 degrees two theta; or which is characterized by an XRPD pattern having peaks at 11.2, 16.3, 17.8, 18.8, 19.9, 21.7, 22.3, 23.4, 26.6, and 27.2 degrees 2-theta ± 0.2 degrees 2-theta.
3. A crystalline form according to any of Claims 1 to 2, which is anhydrous.
4. A crystalline form according to any one of Claims 1-3, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat.
5. A crystalline product according to any of Claims 1-4, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat.
6. Firibastat: piperazine, preferably Firibastat piperazine salt.
7. Firibastat piperazine salt according to Claim 6, which wherein the molar ratio of Firibastat to piperazine is between 1:1.5 and 1.5:1, preferably between 1:1.25 and 1.25:1, about 1:1, or about 1:2, preferably about 1:2.
8. Firibastat: piperazine according to any of Claims 6-7, which is crystalline.
9. Firibastat: piperazine according to Claim 8, designated Form PI, which is characterized by data selected from: d. an XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ±
0.2 degrees 2-theta; or e. an XRPD pattern as depicted in Figure 6.
10. Firibastat: piperazine according to Claim 9, which is characterized by an XRPD pattern having peaks at 12.5, 16.4, 17.6, 19.5 and 22.1 degrees 2-theta ± 0.2 degrees 2-theta, and also having one, two, three or four additional peaks selected from 15.7, 20.0, 20.7, 25.1 and 27.7 degrees two theta ± 0.2 degrees two theta; or which is characterized by an XRPD pattern having peaks at 12.5, 15.7, 16.4, 17.6, 19.5, 20.0, 20.7, 22.1, 25.1 and 27.7 degrees 2-theta ± 0.2 degrees 2-theta.
11. Firibastat: piperazine according to any of Claims 8-10, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of any other crystalline forms of Firibastat: piperazine.
12. Firibastat: piperazine according to any of Claims 8-11, which contains: no more than about 20%, no more than about 10%, no more than about 5%, no more than about 2%, no more than about 1% or about 0% of amorphous Firibastat: piperazine.
13. A pharmaceutical composition comprising a crystalline product according to any of Claims 1-12, and at least one pharmaceutically acceptable excipient.
14. Use of a crystalline product according to any of Claims 1-12, for the preparation of a pharmaceutical composition and/or formulation.
15. A process for preparing the pharmaceutical composition according to Claim 13, comprising combining a crystalline product according to any of Claims 1-12 with at least one pharmaceutically acceptable excipient.
16. A crystalline product according to any of Claims 1-12 or a pharmaceutical composition according to Claim 13, for use as a medicament.
17. A crystalline product according to any of Claims 1-12, or a pharmaceutical composition
according to Claim 13, for use in the treatment of hypertension.
18. A method of treating hypertension comprising administering a therapeutically effective amount of a crystalline product according to any of Claims 1-12, or a pharmaceutical composition according to Claim 13, to a subject in need of the treatment.
19. Use of a crystalline product according to any of Claims 1-12, in the preparation of another solid state form of Firibastat.
20. A process for preparing a solid state form of Firibastat comprising preparing any one or a combination of a crystalline product according to any one of Claims 1-12, and converting it to another a solid state form thereof.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163178063P | 2021-04-22 | 2021-04-22 | |
US63/178,063 | 2021-04-22 | ||
US202163215570P | 2021-06-28 | 2021-06-28 | |
US63/215,570 | 2021-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022225712A1 true WO2022225712A1 (en) | 2022-10-27 |
Family
ID=81448529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/023758 WO2022225712A1 (en) | 2021-04-22 | 2022-04-07 | Solid state forms of firibastat and processes for preparation thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022225712A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004007441A2 (en) | 2002-07-16 | 2004-01-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same |
EP2439192A1 (en) * | 2010-10-07 | 2012-04-11 | Quantum Genomics | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) |
EP2722327A1 (en) * | 2012-10-22 | 2014-04-23 | Quantum Genomics | Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine |
-
2022
- 2022-04-07 WO PCT/US2022/023758 patent/WO2022225712A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004007441A2 (en) | 2002-07-16 | 2004-01-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same |
EP2439192A1 (en) * | 2010-10-07 | 2012-04-11 | Quantum Genomics | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) |
WO2012045849A1 (en) | 2010-10-07 | 2012-04-12 | Quantum Genomics | Method for the preparation of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) |
EP2722327A1 (en) * | 2012-10-22 | 2014-04-23 | Quantum Genomics | Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine |
WO2014064077A1 (en) | 2012-10-22 | 2014-05-01 | Quantum Genomics | Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine |
Non-Patent Citations (3)
Title |
---|
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems" |
HILFIKER, R.: "Polymorphism in the Pharmaceutical Industry", January 2006, WILEY-VCH VERLAG GMBH, Weinheim, ISBN: 978-3-527-31146-0, article HILFIKER R., BLATTER F., VON RAUMER M.: "Relevance of Solid-state Properties for Pharmaceutical Products", pages: 1 - 19, XP002528052 * |
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220259162A1 (en) | Solid state forms of tafamidis and salts thereof | |
US11608318B2 (en) | Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl | |
US20210387952A1 (en) | Solid state forms of daprodustat and process for preparation thereof | |
US20230167090A1 (en) | Solid state forms of aprocitentan and process for preparation thereof | |
US20230339962A1 (en) | Solid state forms of sep-363856 and process for preparation thereof | |
WO2022177927A1 (en) | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt | |
US20230058102A1 (en) | Solid state forms of blarcamesine salts | |
US20240010629A1 (en) | Solid state form of lemborexant | |
US11465974B2 (en) | Crystalline polymorphs of Pracinostat and Pracinostat salts | |
WO2022225712A1 (en) | Solid state forms of firibastat and processes for preparation thereof | |
US20220380316A1 (en) | Solid state forms of arry-797 and process for preparation thereof | |
US20230098234A1 (en) | Solid state forms of mitapivat and process for preparation thereof | |
US20240051964A1 (en) | Solid state forms of capivasertib and process for preparation thereof | |
US20230322786A1 (en) | Solid state forms of at-001 and process for preparation thereof | |
EP4347564A1 (en) | Solid state form of centanafadine hcl and process for preparation thereof | |
EP4229047A1 (en) | Solid state forms of pralsetinib and process for preparation thereof | |
WO2023199258A1 (en) | Solid state forms of mavacamten and process for preparation thereof | |
WO2021216628A1 (en) | Solid state forms of trifarotene and process for preparation thereof | |
WO2024069574A1 (en) | Solid state forms of denifanstat | |
WO2020154581A1 (en) | Solid state forms of fedovapagon-salicyclic acid co-crystal | |
WO2021163397A1 (en) | Solid state forms of avasopasem manganese and process for preparation thereof | |
WO2024089582A1 (en) | Solid state forms of cilofexor salts | |
EP4298088A1 (en) | Solid state forms of tideglusib and process for preparation thereof | |
EP4051659A1 (en) | Solid state forms of fezagepras and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22720141 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22720141 Country of ref document: EP Kind code of ref document: A1 |